<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id><journal-title-group><journal-title>BMC Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25398689</article-id><article-id pub-id-type="pmc">4320624</article-id><article-id pub-id-type="publisher-id">647</article-id><article-id pub-id-type="doi">10.1186/1471-2466-14-176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β<sub>2</sub>-adrenergic agonist, in asthma; a Phase II, randomized study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Singh</surname><given-names>Dave</given-names></name><address><email>dsingh@meu.org.uk</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pujol</surname><given-names>Helena</given-names></name><address><email>helena.pujol@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Ribera</surname><given-names>Anna</given-names></name><address><email>anna.ribera@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Seoane</surname><given-names>Beatriz</given-names></name><address><email>beatriz.seoane@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Massana</surname><given-names>Eric</given-names></name><address><email>eric.massana@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Astbury</surname><given-names>Carol</given-names></name><address><email>carol.astbury@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Ruiz</surname><given-names>Sandrine</given-names></name><address><email>sandrine.ruiz@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>de Miquel</surname><given-names>Gonzalo</given-names></name><address><email>gonzalo.demiquel@almirall.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><aff id="Aff1"><label></label>University of Manchester, Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road, Wythenshawe, Manchester M23 9QZ UK </aff><aff id="Aff2"><label></label>Almirall Research and Development Centre, Barcelona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>176</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>© Singh et al.; licensee BioMed Central. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="4419" xml_f="4429" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4440" xml_f="4453" txt_i="22" txt_f="35">Long-acting β</offsets><sub><offsets xml_i="4458" xml_f="4459" txt_i="35" txt_f="36">2</offsets></sub><offsets xml_i="4465" xml_f="4934" txt_i="36" txt_f="505">-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chronic obstructive pulmonary disease. This study aimed to determine abediterol doses with similar peak bronchodilatory effect to salbutamol 400 μg, and duration of action compatible with once-daily dosing in patients with persistent, stable asthma.</offsets></p></sec><sec><title><offsets xml_i="4956" xml_f="4963" txt_i="507" txt_f="514">Methods</offsets></title><p><offsets xml_i="4974" xml_f="5513" txt_i="515" txt_f="1054">This was a Phase II, randomized, double-blind, double-dummy, crossover, placebo-controlled, dose-ranging study (ClinicalTrials.gov NCT01425801) in 62 patients with mild-to-moderate asthma who were also receiving an ICS. Patients received single doses of abediterol 0.313, 0.625, 1.25, or 2.5 μg, salbutamol 400 μg, or placebo in the morning. Spirometry was performed up to 36 h post-dose; safety and tolerability were assessed throughout the study. The primary endpoint was change from baseline in peak forced expiratory volume in 1 s (FEV</offsets><sub><offsets xml_i="5518" xml_f="5519" txt_i="1054" txt_f="1055">1</offsets></sub><offsets xml_i="5525" xml_f="5568" txt_i="1055" txt_f="1098">). Additional endpoints included trough FEV</offsets><sub><offsets xml_i="5573" xml_f="5574" txt_i="1098" txt_f="1099">1</offsets></sub><offsets xml_i="5580" xml_f="5611" txt_i="1099" txt_f="1130">, normalized area under the FEV</offsets><sub><offsets xml_i="5616" xml_f="5617" txt_i="1130" txt_f="1131">1</offsets></sub><offsets xml_i="5623" xml_f="5634" txt_i="1131" txt_f="1142"> curve (FEV</offsets><sub><offsets xml_i="5639" xml_f="5640" txt_i="1142" txt_f="1143">1</offsets></sub><offsets xml_i="5646" xml_f="5722" txt_i="1143" txt_f="1219"> AUC) up to 24 h post-dose, and peak and trough forced vital capacity (FVC).</offsets></p></sec><sec><title><offsets xml_i="5744" xml_f="5751" txt_i="1221" txt_f="1228">Results</offsets></title><p><offsets xml_i="5762" xml_f="5821" txt_i="1229" txt_f="1288">Abediterol produced dose-dependent improvements in peak FEV</offsets><sub><offsets xml_i="5826" xml_f="5827" txt_i="1288" txt_f="1289">1</offsets></sub><offsets xml_i="5833" xml_f="6077" txt_i="1289" txt_f="1530"> from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 μg, respectively (p &lt; 0.0001 all doses). Abediterol 0.625, 1.25, and 2.5 μg had similar magnitude of peak FEV</offsets><sub><offsets xml_i="6082" xml_f="6083" txt_i="1530" txt_f="1531">1</offsets></sub><offsets xml_i="6089" xml_f="6162" txt_i="1531" txt_f="1604"> effect to salbutamol. Dose-dependent changes from baseline in trough FEV</offsets><sub><offsets xml_i="6167" xml_f="6168" txt_i="1604" txt_f="1605">1</offsets></sub><offsets xml_i="6174" xml_f="6394" txt_i="1605" txt_f="1822"> versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313 to 2.5 μg, respectively (p &lt; 0.0001). All abediterol doses achieved significant improvements versus placebo in FEV</offsets><sub><offsets xml_i="6399" xml_f="6400" txt_i="1822" txt_f="1823">1</offsets></sub><offsets xml_i="6406" xml_f="6724" txt_i="1823" txt_f="2138"> AUC 0–6, 0–12, and 0–24 h, and peak and trough FVC (p &lt; 0.05). Less than 10% of patients experienced treatment-related adverse events for each dose of abediterol; most were mild to moderate in intensity and the most common were headache and nasopharyngitis. There were no clinically relevant changes in heart rate.</offsets></p></sec><sec><title><offsets xml_i="6746" xml_f="6757" txt_i="2140" txt_f="2151">Conclusions</offsets></title><p><offsets xml_i="6768" xml_f="7057" txt_i="2152" txt_f="2441">Abediterol 0.625–2.5 μg provided dose-dependent, clinically and statistically significant bronchodilation versus placebo in patients with asthma, with a peak effect similar to salbutamol and duration of action compatible with once-daily dosing. All doses of abediterol were well tolerated.</offsets></p></sec><sec><title><offsets xml_i="7079" xml_f="7112" txt_i="2443" txt_f="2476">Electronic supplementary material</offsets></title><p><offsets xml_i="7123" xml_f="7261" txt_i="2477" txt_f="2615">The online version of this article (doi:10.1186/1471-2466-14-176) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>LABA</kwd><kwd>Chronic respiratory disease</kwd><kwd>Asthma</kwd><kwd>Dose-finding</kwd><kwd>Bronchodilation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="7671" xml_f="7681" txt_i="2624" txt_f="2634">Background</offsets></title><p><offsets xml_i="7692" xml_f="7704" txt_i="2635" txt_f="2647">The use of β</offsets><sub><offsets xml_i="7709" xml_f="7710" txt_i="2647" txt_f="2648">2</offsets></sub><offsets xml_i="7716" xml_f="7902" txt_i="2648" txt_f="2834">-adrenergic agonist bronchodilators in combination with inhaled corticosteroids (ICSs) to manage the symptoms of asthma is recommended by Global Initiative for Asthma (GINA) guidelines [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7934" xml_f="7935" txt_i="2834" txt_f="2835">1</offsets></xref><offsets xml_i="7942" xml_f="8016" txt_i="2835" txt_f="2909">]. Currently licensed bronchodilators include salbutamol, a short-acting β</offsets><sub><offsets xml_i="8021" xml_f="8022" txt_i="2909" txt_f="2910">2</offsets></sub><offsets xml_i="8028" xml_f="8081" txt_i="2910" txt_f="2963">-adrenergic agonist (SABA) administered as required [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="8113" xml_f="8114" txt_i="2963" txt_f="2964">2</offsets></xref><offsets xml_i="8121" xml_f="8168" txt_i="2964" txt_f="3011">], salmeterol and formoterol, two long-acting β</offsets><sub><offsets xml_i="8173" xml_f="8174" txt_i="3011" txt_f="3012">2</offsets></sub><offsets xml_i="8180" xml_f="8262" txt_i="3012" txt_f="3094">-adrenergic agonists (LABAs) administered twice daily in combination with an ICS [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="8294" xml_f="8295" txt_i="3094" txt_f="3095">3</offsets></xref><offsets xml_i="8302" xml_f="8304" txt_i="3095" txt_f="3097">, </offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="8336" xml_f="8337" txt_i="3097" txt_f="3098">4</offsets></xref><offsets xml_i="8344" xml_f="8476" txt_i="3098" txt_f="3230">], and the recently licensed vilanterol, a LABA administered once daily in fixed-dose combination with the ICS fluticasone furoate [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="8508" xml_f="8509" txt_i="3230" txt_f="3231">5</offsets></xref><offsets xml_i="8516" xml_f="8650" txt_i="3231" txt_f="3365">]. There is ongoing interest to develop once-daily medications to further simplify treatment regimens and improve patient compliance [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="8682" xml_f="8683" txt_i="3365" txt_f="3366">6</offsets></xref><offsets xml_i="8690" xml_f="8692" txt_i="3366" txt_f="3368">].</offsets></p><p><offsets xml_i="8699" xml_f="8880" txt_i="3369" txt_f="3550">Abediterol is a novel, once-daily LABA in clinical development as a fixed-dose combination with an ICS for the treatment of asthma and chronic obstructive pulmonary disease (COPD) [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="8912" xml_f="8913" txt_i="3550" txt_f="3551">7</offsets></xref><offsets xml_i="8920" xml_f="8962" txt_i="3551" txt_f="3593">]. Abediterol displays high affinity for β</offsets><sub><offsets xml_i="8967" xml_f="8968" txt_i="3593" txt_f="3594">2</offsets></sub><offsets xml_i="8974" xml_f="9032" txt_i="3594" txt_f="3652">-adrenoceptors, plus a higher functional selectivity for β</offsets><sub><offsets xml_i="9037" xml_f="9038" txt_i="3652" txt_f="3653">2</offsets></sub><offsets xml_i="9044" xml_f="9065" txt_i="3653" txt_f="3674">-adrenoceptors over β</offsets><sub><offsets xml_i="9070" xml_f="9071" txt_i="3674" txt_f="3675">1</offsets></sub><offsets xml_i="9077" xml_f="9168" txt_i="3675" txt_f="3766">-adrenoceptors than formoterol, indacaterol, vilanterol and olodaterol in cellular models [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="9200" xml_f="9201" txt_i="3766" txt_f="3767">7</offsets></xref><offsets xml_i="9208" xml_f="9209" txt_i="3767" txt_f="3768">–</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9241" xml_f="9242" txt_i="3768" txt_f="3769">9</offsets></xref><offsets xml_i="9249" xml_f="9432" txt_i="3769" txt_f="3952">]. The potency of abediterol is also higher than salmeterol and indacaterol in isolated human bronchi and, in addition to these two LABAs, vilanterol and olodaterol in animal models [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="9464" xml_f="9465" txt_i="3952" txt_f="3953">7</offsets></xref><offsets xml_i="9472" xml_f="9474" txt_i="3953" txt_f="3955">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9507" xml_f="9509" txt_i="3955" txt_f="3957">10</offsets></xref><offsets xml_i="9516" xml_f="9582" txt_i="3957" txt_f="4023">]. Abediterol has a rapid onset and prolonged duration of action [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="9614" xml_f="9615" txt_i="4023" txt_f="4024">7</offsets></xref><offsets xml_i="9622" xml_f="9624" txt_i="4024" txt_f="4026">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9657" xml_f="9659" txt_i="4026" txt_f="4028">10</offsets></xref><offsets xml_i="9666" xml_f="9668" txt_i="4028" txt_f="4030">].</offsets></p><p><offsets xml_i="9675" xml_f="10000" txt_i="4031" txt_f="4356">A Phase II clinical trial in patients with asthma provided results that were consistent with the preclinical data; abediterol resulted in significant improvements in lung function at 5 min post-dose that were greater than improvements seen with salmeterol, and significant bronchodilation was sustained up to 24 h post-dose [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="10033" xml_f="10035" txt_i="4356" txt_f="4358">11</offsets></xref><offsets xml_i="10042" xml_f="10391" txt_i="4358" txt_f="4707">]. These characteristics make abediterol an ideal candidate for once-daily dosing. Moreover, abediterol has a favorable cardiovascular safety and tolerability profile: in anesthetized dogs, abediterol had a lesser effect on heart rate compared with salmeterol, formoterol, and indacaterol at concentrations that produced comparable bronchodilation [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="10423" xml_f="10424" txt_i="4707" txt_f="4708">7</offsets></xref><offsets xml_i="10431" xml_f="10433" txt_i="4708" txt_f="4710">, </offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="10466" xml_f="10468" txt_i="4710" txt_f="4712">12</offsets></xref><offsets xml_i="10475" xml_f="10657" txt_i="4712" txt_f="4894">]. In early phase clinical trials, doses of abediterol ≤10 μg were safe and well tolerated and did not demonstrate any clinically relevant effects on heart rate in healthy subjects [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="10690" xml_f="10692" txt_i="4894" txt_f="4896">13</offsets></xref><offsets xml_i="10699" xml_f="10724" txt_i="4896" txt_f="4921">], patients with asthma [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="10757" xml_f="10759" txt_i="4921" txt_f="4923">14</offsets></xref><offsets xml_i="10766" xml_f="10792" txt_i="4923" txt_f="4949">], or patients with COPD [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="10825" xml_f="10827" txt_i="4949" txt_f="4951">15</offsets></xref><offsets xml_i="10834" xml_f="10836" txt_i="4951" txt_f="4953">].</offsets></p><p><offsets xml_i="10843" xml_f="10955" txt_i="4954" txt_f="5066">Drug regulatory authorities have concerns that excessively high LABA doses may cause unacceptable side effects [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="10988" xml_f="10990" txt_i="5066" txt_f="5068">16</offsets></xref><offsets xml_i="10997" xml_f="11047" txt_i="5068" txt_f="5118">]. The trough forced expiratory volume in 1 s (FEV</offsets><sub><offsets xml_i="11052" xml_f="11053" txt_i="5118" txt_f="5119">1</offsets></sub><offsets xml_i="11059" xml_f="11151" txt_i="5119" txt_f="5211">), measured 24 h after dosing, is an important endpoint to assess once-daily LABA efficacy [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="11184" xml_f="11186" txt_i="5211" txt_f="5213">16</offsets></xref><offsets xml_i="11193" xml_f="11546" txt_i="5213" txt_f="5566">]. The maximum effect achieved soon after dosing, otherwise known as the ‘peak’ effect, is also of interest for efficacy and safety reasons. A very high peak effect may indicate high levels of acute drug exposure that could predispose patients to β-agonist-mediated side effects, such as cardiovascular adverse events, when receiving chronic treatment [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="11579" xml_f="11581" txt_i="5566" txt_f="5568">17</offsets></xref><offsets xml_i="11588" xml_f="11755" txt_i="5568" txt_f="5735">]. Moreover, the ideal pharmacologic characteristic of a once-daily LABA is a low ‘peak to trough ratio’, ensuring relatively stable lung function throughout the day [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="11788" xml_f="11790" txt_i="5735" txt_f="5737">18</offsets></xref><offsets xml_i="11797" xml_f="11799" txt_i="5737" txt_f="5739">].</offsets></p><p><offsets xml_i="11806" xml_f="12173" txt_i="5740" txt_f="6107">The peak effect of salbutamol is well characterized, and causes acute bronchodilation without safety concerns. The bronchodilator response following single-dose administration of salbutamol (4 x 100 μg) is commonly used as one of the diagnostic tests for asthma, as recommended by a joint European Respiratory Society (ERS)/American Thoracic Society (ATS) taskforce [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="12206" xml_f="12208" txt_i="6107" txt_f="6109">19</offsets></xref><offsets xml_i="12215" xml_f="12747" txt_i="6109" txt_f="6641">]. This effect is, therefore, a reasonable benchmark for a novel LABA to achieve and this degree of acute bronchodilation is considered clinically meaningful. A major regulatory agency recommended that the peak effects of abediterol should be compared to those of salbutamol to guide dose selection for further clinical trials in order to avoid a dose that induces a much greater degree of bronchodilation than is necessary for clinical effectiveness, which could increase the potential for safety concerns during chronic treatment.</offsets></p><p><offsets xml_i="12754" xml_f="13171" txt_i="6642" txt_f="7059">We report a placebo-controlled, dose-ranging, crossover study comparing the acute bronchodilator effects of abediterol to salbutamol in patients with persistent stable asthma. The primary aim of the study was to investigate the peak bronchodilatory effect of abediterol versus placebo and to confirm it was in the same range as that of salbutamol. The full profile of lung function over 24 h, including the trough FEV</offsets><sub><offsets xml_i="13176" xml_f="13177" txt_i="7059" txt_f="7060">1</offsets></sub><offsets xml_i="13183" xml_f="13550" txt_i="7060" txt_f="7427">, was also measured. The goal of this study was to enable the selection of abediterol doses for future long-term clinical trials, based on a peak effect similar to that of salbutamol 400 μg metered dose inhaler (MDI), coupled with a trough effect compatible with a 24-h duration of action. This trial design was a specific recommendation by a major regulatory agency.</offsets></p></sec><sec id="Sec2" sec-type="methods"><title><offsets xml_i="13601" xml_f="13608" txt_i="7429" txt_f="7436">Methods</offsets></title><sec id="Sec3"><title><offsets xml_i="13638" xml_f="13650" txt_i="7437" txt_f="7449">Study design</offsets></title><p><offsets xml_i="13661" xml_f="14006" txt_i="7450" txt_f="7795">This was a Phase IIa, randomized, double-blind, double-dummy, 6-way crossover, single-dose, multicenter, dose-ranging study conducted between August 2011 and January 2012. The study was conducted in two sites in the UK and seven in Germany. The study protocol was approved by an independent ethics committee in each country (see Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="14042" xml_f="14043" txt_i="7795" txt_f="7796">1</offsets></xref><offsets xml_i="14050" xml_f="14231" txt_i="7796" txt_f="7977">) and complied with the Declaration of Helsinki and the International Conference on Harmonisation and Good Clinical Practice guidelines. Patients provided written, informed consent.</offsets></p><p><offsets xml_i="14238" xml_f="15060" txt_i="7978" txt_f="8800">Following a screening visit and a 12–16 day run-in period to assess clinical stability, participants were randomized to 1 of 6 treatment sequences according to a balanced Williams design for crossover studies (1:1:1:1:1:1). Block randomization was performed by the Sponsor, using a computer-generated schedule to assign a treatment sequence to each patient randomization number. The block size and randomization schedule were not communicated to investigators. Patients received abediterol 0.313, 0.625, 1.25, or 2.5 μg, salbutamol 400 μg (administered as four inhalations with 100 μg per inhalation), or placebo (at 09:00 h ±1 h) at each visit, with a washout period of 7–14 days. A follow-up telephone call to assess safety was made approximately 2 weeks following the final treatment visit or premature discontinuation.</offsets></p><p><offsets xml_i="15067" xml_f="15165" txt_i="8801" txt_f="8899">Abediterol and placebo to abediterol were administered via a multidose dry powder inhaler (Genuair</offsets><sup><offsets xml_i="15170" xml_f="15171" txt_i="8899" txt_f="8900">®</offsets></sup><offsets xml_i="15177" xml_f="15453" txt_i="8900" txt_f="9176">). Salbutamol and placebo to salbutamol were administered via a pressurized MDI (Ventolin™ Evohaler™). In order to preserve study blinding, independent, trained personnel prepared the medication, delivered the device to patients, and collected the device following inhalation.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="15485" xml_f="15493" txt_i="9178" txt_f="9186">Patients</offsets></title><p><offsets xml_i="15504" xml_f="15701" txt_i="9187" txt_f="9384">Eligible participants were men or women aged 18–70 years with a clinical diagnosis of persistent asthma (according to GINA guidelines) for ≥6 months prior to screening. Eligible patients had an FEV</offsets><sub><offsets xml_i="15706" xml_f="15707" txt_i="9384" txt_f="9385">1</offsets></sub><offsets xml_i="15713" xml_f="15773" txt_i="9385" txt_f="9442"> &gt;60% and ≤85% of the predicted normal value, with an FEV</offsets><sub><offsets xml_i="15778" xml_f="15779" txt_i="9442" txt_f="9443">1</offsets></sub><offsets xml_i="15785" xml_f="15837" txt_i="9443" txt_f="9495"> reversibility ≥12%, and an absolute increase in FEV</offsets><sub><offsets xml_i="15842" xml_f="15843" txt_i="9495" txt_f="9496">1</offsets></sub><offsets xml_i="15849" xml_f="15957" txt_i="9496" txt_f="9604"> of ≥200 mL over their baseline value following inhalation of salbutamol 400 μg at screening. Comparable FEV</offsets><sub><offsets xml_i="15962" xml_f="15963" txt_i="9604" txt_f="9605">1</offsets></sub><offsets xml_i="15969" xml_f="16426" txt_i="9605" txt_f="10062"> measurements were required at screening and pre-dose at each visit in order to ensure there were no carry-over effects from previous treatment periods (limit of variability ±20%). At enrollment, all patients were using only an ICS to control their asthma, and had been on a stable dose and regimen for at least 4 weeks prior to screening, up to the equivalent of 1600 μg/day of beclometasone dipropionate, and had not previously been exposed to abediterol.</offsets></p><p><offsets xml_i="16433" xml_f="16853" txt_i="10063" txt_f="10480">Exclusion criteria included: a smoking history within the past 6 months or &gt;10 pack-years; presence or history of relevant pulmonary disease or any other clinically relevant disease or abnormality as judged by the investigator; difficult-to-treat asthma; any respiratory tract infection ≤6 weeks prior to screening; hospitalization or emergency room treatment for asthma ≤3 months prior to screening; treatment with β</offsets><sub><offsets xml_i="16858" xml_f="16859" txt_i="10480" txt_f="10481">2</offsets></sub><offsets xml_i="16865" xml_f="16927" txt_i="10481" txt_f="10543">-antagonists; and positive laboratory tests for illicit drugs.</offsets></p><p><offsets xml_i="16934" xml_f="17142" txt_i="10544" txt_f="10752">The use of anticholinergics, SABAs (other than salbutamol), LABAs, continuous oral or parenteral corticosteroids, methyl-xanthines, cromolyn sodium, nedocromil, leukotriene modifiers, anti-immunoglobulin E, β</offsets><sub><offsets xml_i="17147" xml_f="17148" txt_i="10752" txt_f="10753">1</offsets></sub><offsets xml_i="17154" xml_f="17537" txt_i="10753" txt_f="11136">-blocking agents, and other investigational drugs was prohibited during the study. Patients using prohibited medications underwent up to 6 weeks’ washout before the screening visit. Salbutamol pressurized MDI (100 μg/puff) was the only reliever medication permitted and was used on an as-needed basis and avoided 6 h prior to and during a treatment visit unless absolutely necessary.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="17569" xml_f="17589" txt_i="11138" txt_f="11158">Efficacy assessments</offsets></title><p><offsets xml_i="17600" xml_f="18172" txt_i="11159" txt_f="11731">Pulmonary function tests were conducted at screening, pre-dose, and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 23, 24, and 36 h post-dose at each treatment visit using standardized spirometers at each investigational site (eResearchTechnology, Philadelphia, PA, USA). Prior to the first spirometry measure, the technician demonstrated the procedure and allowed the patient two practice attempts. At each study time point, the maneuvers were repeated until three technically adequate measurements were made according to ERS/ATS guidelines for acceptability and repeatability [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="18205" xml_f="18207" txt_i="11731" txt_f="11733">20</offsets></xref><offsets xml_i="18214" xml_f="18258" txt_i="11733" txt_f="11777">], with a maximum of eight attempts allowed.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="18290" xml_f="18325" txt_i="11779" txt_f="11814">Safety and tolerability assessments</offsets></title><p><offsets xml_i="18336" xml_f="19092" txt_i="11815" txt_f="12571">Treatment-emergent adverse events (TEAEs), including serious adverse events, were recorded throughout the study and follow-up period. A physical examination was performed at screening and at 36 h post-dose following the last treatment period (Visit 6), and blood pressure and 12-lead electrocardiogram measures were made at screening, pre-dose, and at 0.75, 2, 6, 24 h post-dose for each treatment period, and 36 h post-dose at Visit 6. Clinical laboratory tests (blood chemistry, hematology, urinalysis, and a serum pregnancy test) were performed at screening and at 36 h post-dose at Visit 6. Blood glucose and serum potassium levels were assessed at screening, pre-dose, and at 4, 24 h post-dose for each treatment period, and 36 h post-dose at Visit 6.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="19124" xml_f="19134" txt_i="12573" txt_f="12583">Statistics</offsets></title><p><offsets xml_i="19145" xml_f="19211" txt_i="12584" txt_f="12650">The primary efficacy endpoint was change from baseline in peak FEV</offsets><sub><offsets xml_i="19216" xml_f="19217" txt_i="12650" txt_f="12651">1</offsets></sub><offsets xml_i="19223" xml_f="19251" txt_i="12651" txt_f="12679"> (defined as the highest FEV</offsets><sub><offsets xml_i="19256" xml_f="19257" txt_i="12679" txt_f="12680">1</offsets></sub><offsets xml_i="19263" xml_f="19476" txt_i="12680" txt_f="12893"> value observed within 4 h of the administration of the investigational medicinal product [IMP]) on Day 1. Secondary endpoints included change from baseline in peak forced vital capacity (FVC) on Day 1, trough FEV</offsets><sub><offsets xml_i="19481" xml_f="19482" txt_i="12893" txt_f="12894">1</offsets></sub><offsets xml_i="19488" xml_f="19629" txt_i="12894" txt_f="13035"> (defined as the highest average of the maneuvers performed at 23–24 h post IMP administration) and FVC on Day 2, change from baseline in FEV</offsets><sub><offsets xml_i="19634" xml_f="19635" txt_i="13035" txt_f="13036">1</offsets></sub><offsets xml_i="19641" xml_f="19733" txt_i="13036" txt_f="13128"> and FVC at each time point up to 36 h post-dose, and change from baseline in normalized FEV</offsets><sub><offsets xml_i="19738" xml_f="19739" txt_i="13128" txt_f="13129">1</offsets></sub><offsets xml_i="19745" xml_f="19813" txt_i="13129" txt_f="13197"> area under the curve (AUC; defined as the area between baseline FEV</offsets><sub><offsets xml_i="19818" xml_f="19819" txt_i="13197" txt_f="13198">1</offsets></sub><offsets xml_i="19825" xml_f="19837" txt_i="13198" txt_f="13210"> and the FEV</offsets><sub><offsets xml_i="19842" xml_f="19843" txt_i="13210" txt_f="13211">1</offsets></sub><offsets xml_i="19849" xml_f="19986" txt_i="13211" txt_f="13348"> curve, from 0 to × hours divided by × hours) at 0–6, 0–12, and 0–24 h post-dose. In accordance with the GINA guidelines, a change in FEV</offsets><sub><offsets xml_i="19991" xml_f="19992" txt_i="13348" txt_f="13349">1</offsets></sub><offsets xml_i="19998" xml_f="20045" txt_i="13349" txt_f="13396"> of 200 mL was considered clinically relevant [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="20077" xml_f="20078" txt_i="13396" txt_f="13397">1</offsets></xref><offsets xml_i="20085" xml_f="20087" txt_i="13397" txt_f="13399">].</offsets></p><p><offsets xml_i="20094" xml_f="20208" txt_i="13400" txt_f="13514">A population of 48 patients was necessary to achieve 80% power to detect a 150 mL change from baseline in peak FEV</offsets><sub><offsets xml_i="20213" xml_f="20214" txt_i="13514" txt_f="13515">1</offsets></sub><offsets xml_i="20220" xml_f="20363" txt_i="13515" txt_f="13658"> for any dose of abediterol compared with placebo. Assuming a 15% withdrawal rate, the protocol required at least 54 patients to be randomized.</offsets></p><p><offsets xml_i="20370" xml_f="20617" txt_i="13659" txt_f="13906">All reported efficacy assessments were analyzed in the intention-to-treat population, defined as all randomized patients who took at least one dose of the IMP (placebo, abediterol, or salbutamol) and had at least one baseline and one post-dose FEV</offsets><sub><offsets xml_i="20622" xml_f="20623" txt_i="13906" txt_f="13907">1</offsets></sub><offsets xml_i="20629" xml_f="20940" txt_i="13907" txt_f="14218"> value for at least one treatment visit. Safety analyses are reported in the safety population, which consisted of all randomized patients who took at least one dose of the IMP. All statistical analyses were performed using Statistical Analysis System (SAS Institute Inc., Cary, NC, USA) version 9.1.3 software.</offsets></p><p><offsets xml_i="20947" xml_f="21163" txt_i="14219" txt_f="14435">Efficacy variables were analyzed using an analysis of covariance model for crossover designs, with fixed-effect factors of sequence, treatment, and period, patient within sequence as a random effect, and baseline FEV</offsets><sub><offsets xml_i="21168" xml_f="21169" txt_i="14435" txt_f="14436">1</offsets></sub><offsets xml_i="21175" xml_f="21535" txt_i="14436" txt_f="14796"> or FVC as a covariate, as appropriate. Between-treatments comparisons were performed by means of contrasts on the treatment factor. The difference between treatments was estimated by the difference between the least squares means. Statistical comparisons between active treatments and placebo were two-sided hypothesis tests with a significance level of 0.05.</offsets></p></sec></sec><sec id="Sec8" sec-type="results"><title><offsets xml_i="21592" xml_f="21599" txt_i="14799" txt_f="14806">Results</offsets></title><sec id="Sec9"><title><offsets xml_i="21629" xml_f="21645" txt_i="14807" txt_f="14823">Study population</offsets></title><p><offsets xml_i="21656" xml_f="21817" txt_i="14824" txt_f="14985">A total of 115 patients were screened, with 62 patients randomized (40/62 [64.5%] male, mean age 40.9 ± 11.2 years). Patient demographics are presented in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="21851" xml_f="21852" txt_i="14985" txt_f="14986">1</offsets></xref><offsets xml_i="21859" xml_f="21910" txt_i="14986" txt_f="15037">. A diagram of patient flow is presented in Figure </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="21942" xml_f="21943" txt_i="15037" txt_f="15038">1</offsets></xref><offsets xml_i="21950" xml_f="22494" txt_i="15038" txt_f="15582">. All 62 patients were included in the intention-to-treat and safety populations. One protocol violation occurred when a patient was inadvertently given the treatment scheduled for Visit 6 at Visit 5, and vice versa. Data for this patient were analyzed according to the treatments received. Four patients withdrew or were discontinued from the study: two due to inability to comply with the study schedule, one who did not fulfill stability criteria, and one for unknown reasons (patient did not return for the premature discontinuation visit).</offsets><table-wrap id="Tab1"><label><offsets xml_i="22523" xml_f="22530" txt_i="15582" txt_f="15589">Table 1</offsets></label><caption><p><offsets xml_i="22550" xml_f="22551" txt_i="15589" txt_f="15590">
</offsets><bold><offsets xml_i="22557" xml_f="22608" txt_i="15590" txt_f="15641">Patient demographics at baseline: safety population</offsets></bold><offsets xml_i="22615" xml_f="22616" txt_i="15641" txt_f="15642">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="22691" xml_f="22708" txt_i="15643" txt_f="15660">Patients (N = 62)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="22741" xml_f="22765" txt_i="15660" txt_f="15684">Age, mean no. years (SD)</offsets></td><td><offsets xml_i="22774" xml_f="22785" txt_i="15685" txt_f="15696">40.9 (11.2)</offsets></td></tr><tr><td><offsets xml_i="22803" xml_f="22821" txt_i="15697" txt_f="15715">Male gender, n (%)</offsets></td><td><offsets xml_i="22830" xml_f="22839" txt_i="15716" txt_f="15725">40 (64.5)</offsets></td></tr><tr><td><offsets xml_i="22857" xml_f="22868" txt_i="15726" txt_f="15737">Race, n (%)</offsets></td><td></td></tr><tr><td><offsets xml_i="22895" xml_f="22902" txt_i="15739" txt_f="15746">  White</offsets></td><td><offsets xml_i="22911" xml_f="22920" txt_i="15747" txt_f="15756">58 (93.5)</offsets></td></tr><tr><td><offsets xml_i="22938" xml_f="22945" txt_i="15757" txt_f="15764">  Other</offsets></td><td><offsets xml_i="22954" xml_f="22961" txt_i="15765" txt_f="15772">4 (6.5)</offsets></td></tr><tr><td><offsets xml_i="22979" xml_f="23010" txt_i="15773" txt_f="15804">Cigarette smoking status, n (%)</offsets></td><td></td></tr><tr><td><offsets xml_i="23037" xml_f="23052" txt_i="15806" txt_f="15821">  Former smoker</offsets></td><td><offsets xml_i="23061" xml_f="23070" txt_i="15822" txt_f="15831">21 (33.9)</offsets></td></tr><tr><td><offsets xml_i="23088" xml_f="23102" txt_i="15832" txt_f="15846">  Never smoked</offsets></td><td><offsets xml_i="23111" xml_f="23120" txt_i="15847" txt_f="15856">41 (66.1)</offsets></td></tr><tr><td><offsets xml_i="23138" xml_f="23179" txt_i="15857" txt_f="15898">Smoking history, mean no. pack-years (SD)</offsets></td><td><offsets xml_i="23188" xml_f="23197" txt_i="15899" txt_f="15908">4.6 (3.3)</offsets></td></tr><tr><td><offsets xml_i="23215" xml_f="23251" txt_i="15909" txt_f="15945">Asthma duration, mean no. years (SD)</offsets></td><td><offsets xml_i="23260" xml_f="23271" txt_i="15946" txt_f="15957">25.5 (13.2)</offsets></td></tr><tr><td><offsets xml_i="23289" xml_f="23311" txt_i="15958" txt_f="15980">Asthma severity, n (%)</offsets></td><td></td></tr><tr><td><offsets xml_i="23338" xml_f="23349" txt_i="15982" txt_f="15993">  60% ≤ FEV</offsets><sub><offsets xml_i="23354" xml_f="23355" txt_i="15993" txt_f="15994">1</offsets></sub><offsets xml_i="23361" xml_f="23383" txt_i="15994" txt_f="16013"> &lt; 80% of predicted</offsets></td><td><offsets xml_i="23392" xml_f="23401" txt_i="16014" txt_f="16023">46 (74.2)</offsets></td></tr><tr><td><offsets xml_i="23419" xml_f="23424" txt_i="16024" txt_f="16029">  FEV</offsets><sub><offsets xml_i="23429" xml_f="23430" txt_i="16029" txt_f="16030">1</offsets></sub><offsets xml_i="23436" xml_f="23454" txt_i="16030" txt_f="16048"> ≥80% of predicted</offsets></td><td><offsets xml_i="23463" xml_f="23472" txt_i="16049" txt_f="16058">16 (25.8)</offsets></td></tr><tr><td><offsets xml_i="23490" xml_f="23513" txt_i="16059" txt_f="16082">Bronchial reversibility</offsets><sup><offsets xml_i="23518" xml_f="23519" txt_i="16082" txt_f="16083">a</offsets></sup><offsets xml_i="23525" xml_f="23538" txt_i="16083" txt_f="16096">, mean % (SD)</offsets></td><td><offsets xml_i="23547" xml_f="23557" txt_i="16097" txt_f="16107">21.3 (8.2)</offsets></td></tr><tr><td><offsets xml_i="23575" xml_f="23578" txt_i="16108" txt_f="16111">FEV</offsets><sub><offsets xml_i="23583" xml_f="23584" txt_i="16111" txt_f="16112">1</offsets></sub><offsets xml_i="23590" xml_f="23613" txt_i="16112" txt_f="16135"> absolute reversibility</offsets><sup><offsets xml_i="23618" xml_f="23619" txt_i="16135" txt_f="16136">b</offsets></sup><offsets xml_i="23625" xml_f="23638" txt_i="16136" txt_f="16149">, mean L (SD)</offsets></td><td><offsets xml_i="23647" xml_f="23660" txt_i="16150" txt_f="16163">0.568 (0.261)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="23706" xml_f="23707" txt_i="16164" txt_f="16165">
</offsets><sup><offsets xml_i="23712" xml_f="23713" txt_i="16165" txt_f="16166">a</offsets></sup><offsets xml_i="23719" xml_f="23743" txt_i="16166" txt_f="16190">calculated as 100 x (FEV</offsets><sub><offsets xml_i="23748" xml_f="23749" txt_i="16190" txt_f="16191">1</offsets></sub><offsets xml_i="23755" xml_f="23783" txt_i="16191" txt_f="16219"> [post-bronchodilator] – FEV</offsets><sub><offsets xml_i="23788" xml_f="23789" txt_i="16219" txt_f="16220">1</offsets></sub><offsets xml_i="23795" xml_f="23820" txt_i="16220" txt_f="16245"> [pre-bronchodilator]/FEV</offsets><sub><offsets xml_i="23825" xml_f="23826" txt_i="16245" txt_f="16246">1</offsets></sub><offsets xml_i="23832" xml_f="23856" txt_i="16246" txt_f="16270"> [pre-bronchodilator]); </offsets><sup><offsets xml_i="23861" xml_f="23862" txt_i="16270" txt_f="16271">b</offsets></sup><offsets xml_i="23868" xml_f="23885" txt_i="16271" txt_f="16288">calculated as FEV</offsets><sub><offsets xml_i="23890" xml_f="23891" txt_i="16288" txt_f="16289">1</offsets></sub><offsets xml_i="23897" xml_f="23925" txt_i="16289" txt_f="16317"> (post-bronchodilator) – FEV</offsets><sub><offsets xml_i="23930" xml_f="23931" txt_i="16317" txt_f="16318">1</offsets></sub><offsets xml_i="23937" xml_f="23959" txt_i="16318" txt_f="16340"> (pre-bronchodilator).</offsets></p><p><offsets xml_i="23966" xml_f="23969" txt_i="16341" txt_f="16344">FEV</offsets><sub><offsets xml_i="23974" xml_f="23975" txt_i="16344" txt_f="16345">1</offsets></sub><offsets xml_i="23981" xml_f="24039" txt_i="16345" txt_f="16403">, forced expiratory volume in 1 s; SD, standard deviation.</offsets></p></table-wrap-foot></table-wrap><fig id="Fig1"><label><offsets xml_i="24096" xml_f="24104" txt_i="16404" txt_f="16412">Figure 1</offsets></label><caption><p><offsets xml_i="24124" xml_f="24125" txt_i="16412" txt_f="16413">
</offsets><bold><offsets xml_i="24131" xml_f="24155" txt_i="16413" txt_f="16437">Diagram of patient flow.</offsets></bold><offsets xml_i="24162" xml_f="24163" txt_i="16437" txt_f="16438">
</offsets></p></caption><graphic xlink:href="12890_2014_647_Fig1_HTML" id="d30e812"></graphic></fig></p></sec><sec id="Sec10"><title><offsets xml_i="24286" xml_f="24294" txt_i="16441" txt_f="16449">Efficacy</offsets></title><sec id="Sec11"><title><bold><italic><offsets xml_i="24339" xml_f="24347" txt_i="16450" txt_f="16458">Peak FEV</offsets></italic></bold><sub><bold><italic><offsets xml_i="24382" xml_f="24383" txt_i="16458" txt_f="16459">1</offsets></italic></bold></sub></title><p><offsets xml_i="24416" xml_f="24433" txt_i="16460" txt_f="16477">Mean baseline FEV</offsets><sub><offsets xml_i="24438" xml_f="24439" txt_i="16477" txt_f="16478">1</offsets></sub><offsets xml_i="24445" xml_f="24601" txt_i="16478" txt_f="16634"> values were similar across all treatment periods, ranging from 2.63 L to 2.69 L. The full profile of lung function after each treatment is shown in Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="24633" xml_f="24634" txt_i="16634" txt_f="16635">2</offsets></xref><offsets xml_i="24641" xml_f="24867" txt_i="16635" txt_f="16858">. The onset of action of abediterol was rapid, with significant bronchodilation compared with placebo observed at the first study time point (15 min) post-dose (p &lt; 0.0001 for all doses of abediterol versus placebo, Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="24899" xml_f="24900" txt_i="16858" txt_f="16859">2</offsets></xref><offsets xml_i="24907" xml_f="24990" txt_i="16859" txt_f="16942">a). All doses of abediterol produced significantly greater improvements in peak FEV</offsets><sub><offsets xml_i="24995" xml_f="24996" txt_i="16942" txt_f="16943">1</offsets></sub><offsets xml_i="25002" xml_f="25075" txt_i="16943" txt_f="17013"> from baseline compared with placebo (p &lt; 0.0001 for all doses, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="25109" xml_f="25110" txt_i="17013" txt_f="17014">2</offsets></xref><offsets xml_i="25117" xml_f="25249" txt_i="17014" txt_f="17146">), and the magnitude of effect of abediterol 0.625, 1.25, and 2.5 μg was not significantly different from salbutamol 400 μg (Figure </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="25281" xml_f="25282" txt_i="17146" txt_f="17147">3</offsets></xref><offsets xml_i="25289" xml_f="25297" txt_i="17147" txt_f="17155">, Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="25331" xml_f="25332" txt_i="17155" txt_f="17156">3</offsets></xref><offsets xml_i="25339" xml_f="25409" txt_i="17156" txt_f="17226">). Least squares means differences in change from baseline in peak FEV</offsets><sub><offsets xml_i="25414" xml_f="25415" txt_i="17226" txt_f="17227">1</offsets></sub><offsets xml_i="25421" xml_f="25577" txt_i="17227" txt_f="17383"> versus placebo were 0.274, 0.322, 0.371, and 0.405 L for abediterol 0.313, 0.625, 1.25, and 2.5 μg, respectively, and 0.353 L for salbutamol 400 μg (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="25611" xml_f="25612" txt_i="17383" txt_f="17384">3</offsets></xref><offsets xml_i="25619" xml_f="25645" txt_i="17384" txt_f="17410">). Median time to peak FEV</offsets><sub><offsets xml_i="25650" xml_f="25651" txt_i="17410" txt_f="17411">1</offsets></sub><offsets xml_i="25657" xml_f="25771" txt_i="17411" txt_f="17525"> was 3 h post-dose for abediterol (all doses), 2 h post-dose for placebo, and 1 h post-dose for salbutamol 400 μg.</offsets><fig id="Fig2"><label><offsets xml_i="25793" xml_f="25801" txt_i="17525" txt_f="17533">Figure 2</offsets></label><caption><p><offsets xml_i="25821" xml_f="25822" txt_i="17533" txt_f="17534">
</offsets><bold><offsets xml_i="25828" xml_f="25855" txt_i="17534" txt_f="17561">Change from baseline in FEV</offsets></bold><offsets xml_i="25862" xml_f="25863" txt_i="17561" txt_f="17562">
</offsets><sub><bold><offsets xml_i="25874" xml_f="25875" txt_i="17562" txt_f="17563">1</offsets></bold></sub><offsets xml_i="25888" xml_f="25889" txt_i="17563" txt_f="17564">
</offsets><bold><offsets xml_i="25895" xml_f="25905" txt_i="17564" txt_f="17574">over time.</offsets></bold><offsets xml_i="25912" xml_f="25986" txt_i="17574" txt_f="17648"> Data are presented as least squares means with 95% confidence intervals: </offsets><bold><offsets xml_i="25992" xml_f="25994" txt_i="17648" txt_f="17650">a)</offsets></bold><offsets xml_i="26001" xml_f="26094" txt_i="17650" txt_f="17740"> p &lt; 0.0001 versus placebo for salbutamol and all doses of abediterol at all time points; </offsets><bold><offsets xml_i="26100" xml_f="26102" txt_i="17740" txt_f="17742">b)</offsets></bold><offsets xml_i="26109" xml_f="26340" txt_i="17742" txt_f="17970"> p &lt; 0.0001 for all doses of abediterol 0–24 h post-dose and abediterol 1.25 and 2.5 μg 36 h post-dose versus placebo, p = 0.002 and p = 0.01 for abediterol 0.313 and 0.625 μg, respectively, at 36 h post-dose versus placebo. FEV</offsets><sub><offsets xml_i="26345" xml_f="26346" txt_i="17970" txt_f="17971">1</offsets></sub><offsets xml_i="26352" xml_f="26386" txt_i="17971" txt_f="18005">, forced expiratory volume in 1 s.</offsets></p></caption><graphic xlink:href="12890_2014_647_Fig2_HTML" id="d30e884"></graphic></fig></p><table-wrap id="Tab2"><label><offsets xml_i="26509" xml_f="26516" txt_i="18007" txt_f="18014">Table 2</offsets></label><caption><p><offsets xml_i="26536" xml_f="26537" txt_i="18014" txt_f="18015">
</offsets><bold><offsets xml_i="26543" xml_f="26631" txt_i="18015" txt_f="18103">Change from baseline in pulmonary function parameters (L): intention-to-treat population</offsets></bold><offsets xml_i="26638" xml_f="26639" txt_i="18103" txt_f="18104">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="26714" xml_f="26728" txt_i="18105" txt_f="18119">Placebo N = 59</offsets></th><th><offsets xml_i="26737" xml_f="26761" txt_i="18119" txt_f="18143">Salbutamol 400 μg N = 58</offsets></th><th><offsets xml_i="26770" xml_f="26796" txt_i="18143" txt_f="18169">Abediterol 0.313 μg N = 60</offsets></th><th><offsets xml_i="26805" xml_f="26831" txt_i="18169" txt_f="18195">Abediterol 0.625 μg N = 60</offsets></th><th><offsets xml_i="26840" xml_f="26865" txt_i="18195" txt_f="18220">Abediterol 1.25 μg N = 60</offsets></th><th><offsets xml_i="26874" xml_f="26898" txt_i="18220" txt_f="18244">Abediterol 2.5 μg N = 61</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="26931" xml_f="26939" txt_i="18244" txt_f="18252">Peak FEV</offsets><sub><offsets xml_i="26944" xml_f="26945" txt_i="18252" txt_f="18253">1</offsets></sub><offsets xml_i="26951" xml_f="26952" txt_i="18253" txt_f="18254">
</offsets></td><td><offsets xml_i="26961" xml_f="26974" txt_i="18255" txt_f="18268">0.202 (0.045)</offsets></td><td><offsets xml_i="26983" xml_f="27000" txt_i="18269" txt_f="18286">0.555**** (0.045)</offsets></td><td><offsets xml_i="27009" xml_f="27018" txt_i="18287" txt_f="18296">0.477****</offsets><sup><offsets xml_i="27023" xml_f="27025" txt_i="18296" txt_f="18298">††</offsets></sup><offsets xml_i="27031" xml_f="27039" txt_i="18298" txt_f="18306"> (0.045)</offsets></td><td><offsets xml_i="27048" xml_f="27065" txt_i="18307" txt_f="18324">0.524**** (0.045)</offsets></td><td><offsets xml_i="27074" xml_f="27091" txt_i="18325" txt_f="18342">0.573**** (0.045)</offsets></td><td><offsets xml_i="27100" xml_f="27117" txt_i="18343" txt_f="18360">0.608**** (0.045)</offsets></td></tr><tr><td><offsets xml_i="27135" xml_f="27145" txt_i="18361" txt_f="18371">Trough FEV</offsets><sub><offsets xml_i="27150" xml_f="27151" txt_i="18371" txt_f="18372">1</offsets></sub><offsets xml_i="27157" xml_f="27158" txt_i="18372" txt_f="18373">
</offsets><sup><offsets xml_i="27163" xml_f="27164" txt_i="18373" txt_f="18374">a</offsets></sup><offsets xml_i="27170" xml_f="27171" txt_i="18374" txt_f="18375">
</offsets></td><td><offsets xml_i="27180" xml_f="27194" txt_i="18376" txt_f="18390">-0.054 (0.039)</offsets></td><td><offsets xml_i="27203" xml_f="27217" txt_i="18391" txt_f="18405">-0.076 (0.039)</offsets></td><td><offsets xml_i="27226" xml_f="27235" txt_i="18406" txt_f="18415">0.166****</offsets><sup><offsets xml_i="27240" xml_f="27244" txt_i="18415" txt_f="18419">††††</offsets></sup><offsets xml_i="27250" xml_f="27258" txt_i="18419" txt_f="18427"> (0.039)</offsets></td><td><offsets xml_i="27267" xml_f="27276" txt_i="18428" txt_f="18437">0.205****</offsets><sup><offsets xml_i="27281" xml_f="27285" txt_i="18437" txt_f="18441">††††</offsets></sup><offsets xml_i="27291" xml_f="27299" txt_i="18441" txt_f="18449"> (0.039)</offsets></td><td><offsets xml_i="27308" xml_f="27317" txt_i="18450" txt_f="18459">0.278****</offsets><sup><offsets xml_i="27322" xml_f="27326" txt_i="18459" txt_f="18463">††††</offsets></sup><offsets xml_i="27332" xml_f="27340" txt_i="18463" txt_f="18471"> (0.039)</offsets></td><td><offsets xml_i="27349" xml_f="27358" txt_i="18472" txt_f="18481">0.346****</offsets><sup><offsets xml_i="27363" xml_f="27367" txt_i="18481" txt_f="18485">††††</offsets></sup><offsets xml_i="27373" xml_f="27381" txt_i="18485" txt_f="18493"> (0.039)</offsets></td></tr><tr><td><offsets xml_i="27399" xml_f="27413" txt_i="18494" txt_f="18508">Normalized FEV</offsets><sub><offsets xml_i="27418" xml_f="27419" txt_i="18508" txt_f="18509">1</offsets></sub><offsets xml_i="27425" xml_f="27429" txt_i="18509" txt_f="18513"> AUC</offsets><sub><offsets xml_i="27434" xml_f="27437" txt_i="18513" txt_f="18516">0–6</offsets></sub><offsets xml_i="27443" xml_f="27444" txt_i="18516" txt_f="18517">
</offsets></td><td><offsets xml_i="27453" xml_f="27466" txt_i="18518" txt_f="18531">0.088 (0.039)</offsets></td><td><offsets xml_i="27475" xml_f="27492" txt_i="18532" txt_f="18549">0.347**** (0.039)</offsets></td><td><offsets xml_i="27501" xml_f="27518" txt_i="18550" txt_f="18567">0.354**** (0.038)</offsets></td><td><offsets xml_i="27527" xml_f="27536" txt_i="18568" txt_f="18577">0.403****</offsets><sup><offsets xml_i="27541" xml_f="27542" txt_i="18577" txt_f="18578">†</offsets></sup><offsets xml_i="27548" xml_f="27556" txt_i="18578" txt_f="18586"> (0.038)</offsets></td><td><offsets xml_i="27565" xml_f="27574" txt_i="18587" txt_f="18596">0.461****</offsets><sup><offsets xml_i="27579" xml_f="27583" txt_i="18596" txt_f="18600">††††</offsets></sup><offsets xml_i="27589" xml_f="27597" txt_i="18600" txt_f="18608"> (0.038)</offsets></td><td><offsets xml_i="27606" xml_f="27615" txt_i="18609" txt_f="18618">0.496****</offsets><sup><offsets xml_i="27620" xml_f="27624" txt_i="18618" txt_f="18622">††††</offsets></sup><offsets xml_i="27630" xml_f="27638" txt_i="18622" txt_f="18630"> (0.038)</offsets></td></tr><tr><td><offsets xml_i="27656" xml_f="27670" txt_i="18631" txt_f="18645">Normalized FEV</offsets><sub><offsets xml_i="27675" xml_f="27676" txt_i="18645" txt_f="18646">1</offsets></sub><offsets xml_i="27682" xml_f="27686" txt_i="18646" txt_f="18650"> AUC</offsets><sub><offsets xml_i="27691" xml_f="27695" txt_i="18650" txt_f="18654">0–12</offsets></sub><offsets xml_i="27701" xml_f="27702" txt_i="18654" txt_f="18655">
</offsets></td><td><offsets xml_i="27711" xml_f="27724" txt_i="18656" txt_f="18669">0.063 (0.040)</offsets></td><td><offsets xml_i="27733" xml_f="27750" txt_i="18670" txt_f="18687">0.219**** (0.040)</offsets></td><td><offsets xml_i="27759" xml_f="27768" txt_i="18688" txt_f="18697">0.348****</offsets><sup><offsets xml_i="27773" xml_f="27777" txt_i="18697" txt_f="18701">††††</offsets></sup><offsets xml_i="27783" xml_f="27791" txt_i="18701" txt_f="18709"> (0.039)</offsets></td><td><offsets xml_i="27800" xml_f="27809" txt_i="18710" txt_f="18719">0.393****</offsets><sup><offsets xml_i="27814" xml_f="27818" txt_i="18719" txt_f="18723">††††</offsets></sup><offsets xml_i="27824" xml_f="27832" txt_i="18723" txt_f="18731"> (0.039)</offsets></td><td><offsets xml_i="27841" xml_f="27850" txt_i="18732" txt_f="18741">0.455****</offsets><sup><offsets xml_i="27855" xml_f="27859" txt_i="18741" txt_f="18745">††††</offsets></sup><offsets xml_i="27865" xml_f="27873" txt_i="18745" txt_f="18753"> (0.039)</offsets></td><td><offsets xml_i="27882" xml_f="27891" txt_i="18754" txt_f="18763">0.496****</offsets><sup><offsets xml_i="27896" xml_f="27900" txt_i="18763" txt_f="18767">††††</offsets></sup><offsets xml_i="27906" xml_f="27914" txt_i="18767" txt_f="18775"> (0.040)</offsets></td></tr><tr><td><offsets xml_i="27932" xml_f="27946" txt_i="18776" txt_f="18790">Normalized FEV</offsets><sub><offsets xml_i="27951" xml_f="27952" txt_i="18790" txt_f="18791">1</offsets></sub><offsets xml_i="27958" xml_f="27962" txt_i="18791" txt_f="18795"> AUC</offsets><sub><offsets xml_i="27967" xml_f="27971" txt_i="18795" txt_f="18799">0–24</offsets></sub><offsets xml_i="27977" xml_f="27978" txt_i="18799" txt_f="18800">
</offsets></td><td><offsets xml_i="27987" xml_f="28000" txt_i="18801" txt_f="18814">0.007 (0.039)</offsets></td><td><offsets xml_i="28009" xml_f="28024" txt_i="18815" txt_f="18830">0.100** (0.039)</offsets></td><td><offsets xml_i="28033" xml_f="28042" txt_i="18831" txt_f="18840">0.282****</offsets><sup><offsets xml_i="28047" xml_f="28051" txt_i="18840" txt_f="18844">††††</offsets></sup><offsets xml_i="28057" xml_f="28065" txt_i="18844" txt_f="18852"> (0.039)</offsets></td><td><offsets xml_i="28074" xml_f="28083" txt_i="18853" txt_f="18862">0.321****</offsets><sup><offsets xml_i="28088" xml_f="28092" txt_i="18862" txt_f="18866">††††</offsets></sup><offsets xml_i="28098" xml_f="28106" txt_i="18866" txt_f="18874"> (0.038)</offsets></td><td><offsets xml_i="28115" xml_f="28124" txt_i="18875" txt_f="18884">0.390****</offsets><sup><offsets xml_i="28129" xml_f="28133" txt_i="18884" txt_f="18888">††††</offsets></sup><offsets xml_i="28139" xml_f="28147" txt_i="18888" txt_f="18896"> (0.038)</offsets></td><td><offsets xml_i="28156" xml_f="28165" txt_i="18897" txt_f="18906">0.446****</offsets><sup><offsets xml_i="28170" xml_f="28174" txt_i="18906" txt_f="18910">††††</offsets></sup><offsets xml_i="28180" xml_f="28188" txt_i="18910" txt_f="18918"> (0.039)</offsets></td></tr><tr><td><offsets xml_i="28206" xml_f="28214" txt_i="18919" txt_f="18927">Peak FVC</offsets></td><td><offsets xml_i="28223" xml_f="28236" txt_i="18928" txt_f="18941">0.222 (0.034)</offsets></td><td><offsets xml_i="28245" xml_f="28262" txt_i="18942" txt_f="18959">0.361**** (0.034)</offsets></td><td><offsets xml_i="28271" xml_f="28286" txt_i="18960" txt_f="18975">0.317** (0.034)</offsets></td><td><offsets xml_i="28295" xml_f="28311" txt_i="18976" txt_f="18992">0.329*** (0.034)</offsets></td><td><offsets xml_i="28320" xml_f="28337" txt_i="18993" txt_f="19010">0.361**** (0.034)</offsets></td><td><offsets xml_i="28346" xml_f="28363" txt_i="19011" txt_f="19028">0.380**** (0.034)</offsets></td></tr><tr><td><offsets xml_i="28381" xml_f="28391" txt_i="19029" txt_f="19039">Trough FVC</offsets><sup><offsets xml_i="28396" xml_f="28397" txt_i="19039" txt_f="19040">a</offsets></sup><offsets xml_i="28403" xml_f="28404" txt_i="19040" txt_f="19041">
</offsets></td><td><offsets xml_i="28413" xml_f="28427" txt_i="19042" txt_f="19056">-0.028 (0.035)</offsets></td><td><offsets xml_i="28436" xml_f="28450" txt_i="19057" txt_f="19071">-0.065 (0.035)</offsets></td><td><offsets xml_i="28459" xml_f="28466" txt_i="19072" txt_f="19079">0.094**</offsets><sup><offsets xml_i="28471" xml_f="28475" txt_i="19079" txt_f="19083">††††</offsets></sup><offsets xml_i="28481" xml_f="28489" txt_i="19083" txt_f="19091"> (0.035)</offsets></td><td><offsets xml_i="28498" xml_f="28504" txt_i="19092" txt_f="19098">0.050*</offsets><sup><offsets xml_i="28509" xml_f="28511" txt_i="19098" txt_f="19100">††</offsets></sup><offsets xml_i="28517" xml_f="28525" txt_i="19100" txt_f="19108"> (0.035)</offsets></td><td><offsets xml_i="28534" xml_f="28542" txt_i="19109" txt_f="19117">0.111***</offsets><sup><offsets xml_i="28547" xml_f="28551" txt_i="19117" txt_f="19121">††††</offsets></sup><offsets xml_i="28557" xml_f="28565" txt_i="19121" txt_f="19129"> (0.035)</offsets></td><td><offsets xml_i="28574" xml_f="28582" txt_i="19130" txt_f="19138">0.120***</offsets><sup><offsets xml_i="28587" xml_f="28591" txt_i="19138" txt_f="19142">††††</offsets></sup><offsets xml_i="28597" xml_f="28605" txt_i="19142" txt_f="19150"> (0.035)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="28651" xml_f="28697" txt_i="19151" txt_f="19197">Data are least squares means (standard error).</offsets></p><p><offsets xml_i="28704" xml_f="28705" txt_i="19198" txt_f="19199">
</offsets><sup><offsets xml_i="28710" xml_f="28711" txt_i="19199" txt_f="19200">a</offsets></sup><offsets xml_i="28717" xml_f="28786" txt_i="19200" txt_f="19269">trough values are the mean of the 23 and 24 h post-dose measurements.</offsets></p><p><offsets xml_i="28793" xml_f="28873" txt_i="19270" txt_f="19338">*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001 versus placebo; </offsets><sup><offsets xml_i="28878" xml_f="28879" txt_i="19338" txt_f="19339">†</offsets></sup><offsets xml_i="28885" xml_f="28898" txt_i="19339" txt_f="19349">p &lt; 0.05, </offsets><sup><offsets xml_i="28903" xml_f="28905" txt_i="19349" txt_f="19351">††</offsets></sup><offsets xml_i="28911" xml_f="28924" txt_i="19351" txt_f="19361">p &lt; 0.01, </offsets><sup><offsets xml_i="28929" xml_f="28933" txt_i="19361" txt_f="19365">††††</offsets></sup><offsets xml_i="28939" xml_f="29003" txt_i="19365" txt_f="19426">p &lt; 0.0001 versus salbutamol 400 μg (analysis of covariance).</offsets></p><p><offsets xml_i="29010" xml_f="29033" txt_i="19427" txt_f="19450">AUC, area under the FEV</offsets><sub><offsets xml_i="29038" xml_f="29039" txt_i="19450" txt_f="19451">1</offsets></sub><offsets xml_i="29045" xml_f="29056" txt_i="19451" txt_f="19462"> curve; FEV</offsets><sub><offsets xml_i="29061" xml_f="29062" txt_i="19462" txt_f="19463">1</offsets></sub><offsets xml_i="29068" xml_f="29130" txt_i="19463" txt_f="19525">, forced expiratory volume in 1 s; FVC, forced vital capacity.</offsets></p></table-wrap-foot></table-wrap><fig id="Fig3"><label><offsets xml_i="29187" xml_f="29195" txt_i="19526" txt_f="19534">Figure 3</offsets></label><caption><p><offsets xml_i="29215" xml_f="29216" txt_i="19534" txt_f="19535">
</offsets><bold><offsets xml_i="29222" xml_f="29254" txt_i="19535" txt_f="19567">Change from baseline in peak FEV</offsets></bold><offsets xml_i="29261" xml_f="29262" txt_i="19567" txt_f="19568">
</offsets><sub><bold><offsets xml_i="29273" xml_f="29274" txt_i="19568" txt_f="19569">1</offsets></bold></sub><offsets xml_i="29287" xml_f="29288" txt_i="19569" txt_f="19570">
</offsets><bold><offsets xml_i="29294" xml_f="29303" txt_i="19570" txt_f="19579">at Day 1.</offsets></bold><offsets xml_i="29310" xml_f="29530" txt_i="19579" txt_f="19787"> Data are presented as least squares means ± standard error: p &lt; 0.0001 versus placebo for all doses of abediterol and salbutamol 400 μg; **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001 (analysis of covariance). FEV</offsets><sub><offsets xml_i="29535" xml_f="29536" txt_i="19787" txt_f="19788">1</offsets></sub><offsets xml_i="29542" xml_f="29576" txt_i="19788" txt_f="19822">, forced expiratory volume in 1 s.</offsets></p></caption><graphic xlink:href="12890_2014_647_Fig3_HTML" id="d30e1217"></graphic></fig><table-wrap id="Tab3"><label><offsets xml_i="29696" xml_f="29703" txt_i="19823" txt_f="19830">Table 3</offsets></label><caption><p><offsets xml_i="29723" xml_f="29724" txt_i="19830" txt_f="19831">
</offsets><bold><offsets xml_i="29730" xml_f="29752" txt_i="19831" txt_f="19853">Comparison of peak FEV</offsets></bold><offsets xml_i="29759" xml_f="29760" txt_i="19853" txt_f="19854">
</offsets><sub><bold><offsets xml_i="29771" xml_f="29772" txt_i="19854" txt_f="19855">1</offsets></bold></sub><offsets xml_i="29785" xml_f="29786" txt_i="19855" txt_f="19856">
</offsets><bold><offsets xml_i="29792" xml_f="29854" txt_i="19856" txt_f="19918">for abediterol versus placebo and abediterol versus salbutamol</offsets></bold><offsets xml_i="29861" xml_f="29862" txt_i="19918" txt_f="19919">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="29937" xml_f="29983" txt_i="19920" txt_f="19966">Least–squares mean difference (standard error)</offsets></th><th><offsets xml_i="29992" xml_f="30015" txt_i="19966" txt_f="19989">95% confidence interval</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="30048" xml_f="30077" txt_i="19989" txt_f="20018">Abediterol 2.5 μg vs. placebo</offsets></td><td><offsets xml_i="30086" xml_f="30099" txt_i="20019" txt_f="20032">0.405 (0.027)</offsets></td><td><offsets xml_i="30108" xml_f="30120" txt_i="20033" txt_f="20045">0.353, 0.458</offsets></td></tr><tr><td><offsets xml_i="30138" xml_f="30168" txt_i="20046" txt_f="20076">Abediterol 1.25 μg vs. placebo</offsets></td><td><offsets xml_i="30177" xml_f="30190" txt_i="20077" txt_f="20090">0.371 (0.027)</offsets></td><td><offsets xml_i="30199" xml_f="30211" txt_i="20091" txt_f="20103">0.318, 0.424</offsets></td></tr><tr><td><offsets xml_i="30229" xml_f="30260" txt_i="20104" txt_f="20135">Abediterol 0.625 μg vs. placebo</offsets></td><td><offsets xml_i="30269" xml_f="30282" txt_i="20136" txt_f="20149">0.322 (0.027)</offsets></td><td><offsets xml_i="30291" xml_f="30303" txt_i="20150" txt_f="20162">0.269, 0.375</offsets></td></tr><tr><td><offsets xml_i="30321" xml_f="30352" txt_i="20163" txt_f="20194">Abediterol 0.313 μg vs. placebo</offsets></td><td><offsets xml_i="30361" xml_f="30374" txt_i="20195" txt_f="20208">0.274 (0.027)</offsets></td><td><offsets xml_i="30383" xml_f="30395" txt_i="20209" txt_f="20221">0.221, 0.327</offsets></td></tr><tr><td><offsets xml_i="30413" xml_f="30442" txt_i="20222" txt_f="20251">Salbutamol 400 μg vs. placebo</offsets></td><td><offsets xml_i="30451" xml_f="30464" txt_i="20252" txt_f="20265">0.353 (0.027)</offsets></td><td><offsets xml_i="30473" xml_f="30485" txt_i="20266" txt_f="20278">0.299, 0.406</offsets></td></tr><tr><td><offsets xml_i="30503" xml_f="30542" txt_i="20279" txt_f="20318">Abediterol 2.5 μg vs. salbutamol 400 μg</offsets></td><td><offsets xml_i="30551" xml_f="30566" txt_i="20319" txt_f="20334">0.0529 (0.0270)</offsets></td><td><offsets xml_i="30575" xml_f="30590" txt_i="20335" txt_f="20350">-0.0002, 0.1061</offsets></td></tr><tr><td><offsets xml_i="30608" xml_f="30648" txt_i="20351" txt_f="20391">Abediterol 1.25 μg vs. salbutamol 400 μg</offsets></td><td><offsets xml_i="30657" xml_f="30672" txt_i="20392" txt_f="20407">0.0181 (0.0269)</offsets></td><td><offsets xml_i="30681" xml_f="30696" txt_i="20408" txt_f="20423">-0.0350, 0.0711</offsets></td></tr><tr><td><offsets xml_i="30714" xml_f="30755" txt_i="20424" txt_f="20465">Abediterol 0.625 μg vs. salbutamol 400 μg</offsets></td><td><offsets xml_i="30764" xml_f="30780" txt_i="20466" txt_f="20482">-0.0308 (0.0269)</offsets></td><td><offsets xml_i="30789" xml_f="30803" txt_i="20483" txt_f="20497">-0.839, 0.0223</offsets></td></tr><tr><td><offsets xml_i="30821" xml_f="30862" txt_i="20498" txt_f="20539">Abediterol 0.313 μg vs. salbutamol 400 μg</offsets></td><td><offsets xml_i="30871" xml_f="30887" txt_i="20540" txt_f="20556">-0.0783 (0.0269)</offsets></td><td><offsets xml_i="30896" xml_f="30912" txt_i="20557" txt_f="20573">-0.1313, -0.0253</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="30958" xml_f="31048" txt_i="20574" txt_f="20664">Data included for comparisons of all doses of abediterol with placebo and with salbutamol.</offsets></p></table-wrap-foot></table-wrap></sec><sec id="Sec12"><title><bold><italic><offsets xml_i="31126" xml_f="31136" txt_i="20666" txt_f="20676">Trough FEV</offsets></italic></bold><sub><bold><italic><offsets xml_i="31171" xml_f="31172" txt_i="20676" txt_f="20677">1</offsets></italic></bold></sub></title><p><offsets xml_i="31205" xml_f="31247" txt_i="20678" txt_f="20720">Statistically significant increases in FEV</offsets><sub><offsets xml_i="31252" xml_f="31253" txt_i="20720" txt_f="20721">1</offsets></sub><offsets xml_i="31259" xml_f="31383" txt_i="20721" txt_f="20842"> were sustained at 24 h post-dose compared with placebo (p &lt; 0.0001 for all doses of abediterol 0–24 h post-dose, Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="31415" xml_f="31416" txt_i="20842" txt_f="20843">2</offsets></xref><offsets xml_i="31423" xml_f="31471" txt_i="20843" txt_f="20891">b). Abediterol significantly improved trough FEV</offsets><sub><offsets xml_i="31476" xml_f="31477" txt_i="20891" txt_f="20892">1</offsets></sub><offsets xml_i="31483" xml_f="31557" txt_i="20892" txt_f="20963"> from baseline compared with placebo (p &lt; 0.0001 for all doses; Figure </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="31589" xml_f="31590" txt_i="20963" txt_f="20964">4</offsets></xref><offsets xml_i="31597" xml_f="31669" txt_i="20964" txt_f="21036">). Least squares means differences in change from baseline in trough FEV</offsets><sub><offsets xml_i="31674" xml_f="31675" txt_i="21036" txt_f="21037">1</offsets></sub><offsets xml_i="31681" xml_f="31896" txt_i="21037" txt_f="21252"> versus placebo were 0.219 L (95% CI 0.136, 0.302), 0.259 L (95% CI 0.176, 0.342), 0.332 L (95% CI 0.249, 0.415), and 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313, 0.625, 1.25, and 2.5 μg, respectively (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="31930" xml_f="31931" txt_i="21252" txt_f="21253">2</offsets></xref><offsets xml_i="31938" xml_f="31973" txt_i="21253" txt_f="21288">). The effects of salbutamol on FEV</offsets><sub><offsets xml_i="31978" xml_f="31979" txt_i="21288" txt_f="21289">1</offsets></sub><offsets xml_i="31985" xml_f="32057" txt_i="21289" txt_f="21361"> were not sustained after 6 h post-dose, as expected for a SABA (Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="32089" xml_f="32090" txt_i="21361" txt_f="21362">2</offsets></xref><offsets xml_i="32097" xml_f="32100" txt_i="21362" txt_f="21365">b).</offsets><fig id="Fig4"><label><offsets xml_i="32122" xml_f="32130" txt_i="21365" txt_f="21373">Figure 4</offsets></label><caption><p><offsets xml_i="32150" xml_f="32151" txt_i="21373" txt_f="21374">
</offsets><bold><offsets xml_i="32157" xml_f="32191" txt_i="21374" txt_f="21408">Change from baseline in trough FEV</offsets></bold><offsets xml_i="32198" xml_f="32199" txt_i="21408" txt_f="21409">
</offsets><sub><bold><offsets xml_i="32210" xml_f="32211" txt_i="21409" txt_f="21410">1</offsets></bold></sub><offsets xml_i="32224" xml_f="32225" txt_i="21410" txt_f="21411">
</offsets><bold><offsets xml_i="32231" xml_f="32240" txt_i="21411" txt_f="21420">at Day 2.</offsets></bold><offsets xml_i="32247" xml_f="32445" txt_i="21420" txt_f="21606"> Data are presented as least squares means ± standard error: p &lt; 0.0001 versus placebo for all doses of abediterol; **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001 (analysis of covariance). FEV</offsets><sub><offsets xml_i="32450" xml_f="32451" txt_i="21606" txt_f="21607">1</offsets></sub><offsets xml_i="32457" xml_f="32491" txt_i="21607" txt_f="21641">, forced expiratory volume in 1 s.</offsets></p></caption><graphic xlink:href="12890_2014_647_Fig4_HTML" id="d30e1397"></graphic></fig></p></sec><sec id="Sec13"><title><bold><italic><offsets xml_i="32629" xml_f="32632" txt_i="21644" txt_f="21647">FEV</offsets></italic></bold><sub><bold><italic><offsets xml_i="32667" xml_f="32668" txt_i="21647" txt_f="21648">1</offsets></italic></bold></sub><bold><italic><offsets xml_i="32704" xml_f="32707" txt_i="21648" txt_f="21651">AUC</offsets></italic></bold></title><p><offsets xml_i="32734" xml_f="32772" txt_i="21652" txt_f="21690">Change from baseline in normalized FEV</offsets><sub><offsets xml_i="32777" xml_f="32778" txt_i="21690" txt_f="21691">1</offsets></sub><offsets xml_i="32784" xml_f="32788" txt_i="21691" txt_f="21695"> AUC</offsets><sub><offsets xml_i="32793" xml_f="32796" txt_i="21695" txt_f="21698">0–6</offsets></sub><offsets xml_i="32802" xml_f="32807" txt_i="21698" txt_f="21703">, FEV</offsets><sub><offsets xml_i="32812" xml_f="32813" txt_i="21703" txt_f="21704">1</offsets></sub><offsets xml_i="32819" xml_f="32823" txt_i="21704" txt_f="21708"> AUC</offsets><sub><offsets xml_i="32828" xml_f="32832" txt_i="21708" txt_f="21712">0–12</offsets></sub><offsets xml_i="32838" xml_f="32847" txt_i="21712" txt_f="21721">, and FEV</offsets><sub><offsets xml_i="32852" xml_f="32853" txt_i="21721" txt_f="21722">1</offsets></sub><offsets xml_i="32859" xml_f="32863" txt_i="21722" txt_f="21726"> AUC</offsets><sub><offsets xml_i="32868" xml_f="32872" txt_i="21726" txt_f="21730">0–24</offsets></sub><offsets xml_i="32878" xml_f="32977" txt_i="21730" txt_f="21826"> was significantly higher for all doses of abediterol versus placebo (p &lt; 0.0001 for all, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="33011" xml_f="33012" txt_i="21826" txt_f="21827">2</offsets></xref><offsets xml_i="33019" xml_f="33100" txt_i="21827" txt_f="21908">), with dose-related effects observed. The change from baseline in normalized FEV</offsets><sub><offsets xml_i="33105" xml_f="33106" txt_i="21908" txt_f="21909">1</offsets></sub><offsets xml_i="33112" xml_f="33116" txt_i="21909" txt_f="21913"> AUC</offsets><sub><offsets xml_i="33121" xml_f="33124" txt_i="21913" txt_f="21916">0–6</offsets></sub><offsets xml_i="33130" xml_f="33230" txt_i="21916" txt_f="22013"> was significantly greater for abediterol 0.625–2.5 μg versus salbutamol 400 μg (p &lt; 0.05, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="33264" xml_f="33265" txt_i="22013" txt_f="22014">2</offsets></xref><offsets xml_i="33272" xml_f="33274" txt_i="22014" txt_f="22016">).</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="33307" xml_f="33310" txt_i="22018" txt_f="22021">FVC</offsets></title><p><offsets xml_i="33321" xml_f="33550" txt_i="22022" txt_f="22248">Mean baseline FVC values were comparable across treatment periods, ranging from 4.23 L to 4.30 L. Abediterol produced significantly greater change from baseline in peak FVC compared with placebo (p &lt; 0.01 for all doses, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="33584" xml_f="33585" txt_i="22248" txt_f="22249">2</offsets></xref><offsets xml_i="33592" xml_f="33807" txt_i="22249" txt_f="22461">). The change from baseline in peak FVC was similar to that observed with salbutamol. Additionally, abediterol significantly improved trough FVC from baseline compared with placebo (p &lt; 0.05 for all doses, Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="33841" xml_f="33842" txt_i="22461" txt_f="22462">2</offsets></xref><offsets xml_i="33849" xml_f="33998" txt_i="22462" txt_f="22608">). All doses of abediterol significantly (p &lt; 0.05) increased FVC versus placebo up to 24 h post-dose except for the 0.625 μg dose at 12 and 23 h.</offsets></p></sec></sec><sec id="Sec15"><title><offsets xml_i="34037" xml_f="34060" txt_i="22611" txt_f="22634">Safety and tolerability</offsets></title><p><offsets xml_i="34071" xml_f="34164" txt_i="22635" txt_f="22728">The percentage of patients experiencing TEAEs was similar across all treatment groups (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="34198" xml_f="34199" txt_i="22728" txt_f="22729">4</offsets></xref><offsets xml_i="34206" xml_f="34782" txt_i="22729" txt_f="23302">). Most TEAEs were mild to moderate in intensity, no patient discontinued the study due to a TEAE, and there were no serious adverse events or deaths. The most common TEAEs were headache and nasopharyngitis, reported by 41.9 and 27.4% of patients, respectively. The percentage of patients that experienced at least one treatment-related TEAE was &lt;10% for all doses of abediterol, and was similar to that of salbutamol and placebo. No clinically significant changes in serum glucose or potassium concentrations were observed over time in any of the treatments groups (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="34816" xml_f="34817" txt_i="23302" txt_f="23303">5</offsets></xref><offsets xml_i="34824" xml_f="34997" txt_i="23303" txt_f="23476">). Minor variations in heart rate over time were observed for all treatment groups, including placebo; none were considered to be dose related or clinically relevant (Table </offsets><xref rid="Tab5" ref-type="table"><offsets xml_i="35031" xml_f="35032" txt_i="23476" txt_f="23477">5</offsets></xref><offsets xml_i="35039" xml_f="35162" txt_i="23477" txt_f="23600">). There were no clinically relevant changes in clinical laboratory tests, blood pressure, or electrocardiogram parameters.</offsets><table-wrap id="Tab4"><label><offsets xml_i="35191" xml_f="35198" txt_i="23600" txt_f="23607">Table 4</offsets></label><caption><p><offsets xml_i="35218" xml_f="35219" txt_i="23607" txt_f="23608">
</offsets><bold><offsets xml_i="35225" xml_f="35301" txt_i="23608" txt_f="23684">TEAEs occurring in ≥2% of patients in any treatment group: safety population</offsets></bold><offsets xml_i="35308" xml_f="35309" txt_i="23684" txt_f="23685">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="7"><offsets xml_i="35396" xml_f="35434" txt_i="23686" txt_f="23724">Number (%) of patients reporting TEAEs</offsets></th></tr><tr><th></th><th><offsets xml_i="35461" xml_f="35475" txt_i="23724" txt_f="23738">Placebo N = 59</offsets></th><th><offsets xml_i="35484" xml_f="35508" txt_i="23738" txt_f="23762">Salbutamol 400 μg N = 58</offsets></th><th><offsets xml_i="35517" xml_f="35543" txt_i="23762" txt_f="23788">Abediterol 0.313 μg N = 60</offsets></th><th><offsets xml_i="35552" xml_f="35578" txt_i="23788" txt_f="23814">Abediterol 0.625 μg N = 60</offsets></th><th><offsets xml_i="35587" xml_f="35612" txt_i="23814" txt_f="23839">Abediterol 1.25 μg N = 60</offsets></th><th><offsets xml_i="35621" xml_f="35645" txt_i="23839" txt_f="23863">Abediterol 2.5 μg N = 61</offsets></th><th><offsets xml_i="35654" xml_f="35666" txt_i="23863" txt_f="23875">Total N = 62</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="35699" xml_f="35707" txt_i="23875" txt_f="23883">Any TEAE</offsets></td><td><offsets xml_i="35716" xml_f="35725" txt_i="23884" txt_f="23893">16 (27.1)</offsets></td><td><offsets xml_i="35734" xml_f="35743" txt_i="23894" txt_f="23903">12 (20.7)</offsets></td><td><offsets xml_i="35752" xml_f="35761" txt_i="23904" txt_f="23913">18 (30.0)</offsets></td><td><offsets xml_i="35770" xml_f="35779" txt_i="23914" txt_f="23923">16 (26.7)</offsets></td><td><offsets xml_i="35788" xml_f="35797" txt_i="23924" txt_f="23933">18 (30.0)</offsets></td><td><offsets xml_i="35806" xml_f="35815" txt_i="23934" txt_f="23943">23 (37.7)</offsets></td><td><offsets xml_i="35824" xml_f="35833" txt_i="23944" txt_f="23953">51 (82.3)</offsets></td></tr><tr><td><offsets xml_i="35851" xml_f="35861" txt_i="23954" txt_f="23964">  Headache</offsets></td><td><offsets xml_i="35870" xml_f="35878" txt_i="23965" txt_f="23973">7 (11.9)</offsets></td><td><offsets xml_i="35887" xml_f="35895" txt_i="23974" txt_f="23982">6 (10.3)</offsets></td><td><offsets xml_i="35904" xml_f="35911" txt_i="23983" txt_f="23990">4 (6.7)</offsets></td><td><offsets xml_i="35920" xml_f="35928" txt_i="23991" txt_f="23999">7 (11.7)</offsets></td><td><offsets xml_i="35937" xml_f="35945" txt_i="24000" txt_f="24008">8 (13.3)</offsets></td><td><offsets xml_i="35954" xml_f="35962" txt_i="24009" txt_f="24017">7 (11.5)</offsets></td><td><offsets xml_i="35971" xml_f="35980" txt_i="24018" txt_f="24027">26 (41.9)</offsets></td></tr><tr><td><offsets xml_i="35998" xml_f="36015" txt_i="24028" txt_f="24045">  Nasopharyngitis</offsets></td><td><offsets xml_i="36024" xml_f="36031" txt_i="24046" txt_f="24053">1 (1.7)</offsets></td><td><offsets xml_i="36040" xml_f="36041" txt_i="24054" txt_f="24055">0</offsets></td><td><offsets xml_i="36050" xml_f="36058" txt_i="24056" txt_f="24064">8 (13.3)</offsets></td><td><offsets xml_i="36067" xml_f="36074" txt_i="24065" txt_f="24072">3 (5.0)</offsets></td><td><offsets xml_i="36083" xml_f="36090" txt_i="24073" txt_f="24080">4 (6.7)</offsets></td><td><offsets xml_i="36099" xml_f="36106" txt_i="24081" txt_f="24088">2 (3.3)</offsets></td><td><offsets xml_i="36115" xml_f="36124" txt_i="24089" txt_f="24098">17 (27.4)</offsets></td></tr><tr><td><offsets xml_i="36142" xml_f="36160" txt_i="24099" txt_f="24117">  Chest discomfort</offsets></td><td><offsets xml_i="36169" xml_f="36176" txt_i="24118" txt_f="24125">2 (3.4)</offsets></td><td><offsets xml_i="36185" xml_f="36186" txt_i="24126" txt_f="24127">0</offsets></td><td><offsets xml_i="36195" xml_f="36202" txt_i="24128" txt_f="24135">1 (1.7)</offsets></td><td><offsets xml_i="36211" xml_f="36212" txt_i="24136" txt_f="24137">0</offsets></td><td><offsets xml_i="36221" xml_f="36222" txt_i="24138" txt_f="24139">0</offsets></td><td><offsets xml_i="36231" xml_f="36238" txt_i="24140" txt_f="24147">2 (3.3)</offsets></td><td><offsets xml_i="36247" xml_f="36254" txt_i="24148" txt_f="24155">5 (8.1)</offsets></td></tr><tr><td><offsets xml_i="36272" xml_f="36282" txt_i="24156" txt_f="24166">  Wheezing</offsets></td><td><offsets xml_i="36291" xml_f="36298" txt_i="24167" txt_f="24174">1 (1.7)</offsets></td><td><offsets xml_i="36307" xml_f="36314" txt_i="24175" txt_f="24182">2 (3.4)</offsets></td><td><offsets xml_i="36323" xml_f="36330" txt_i="24183" txt_f="24190">1 (1.7)</offsets></td><td><offsets xml_i="36339" xml_f="36340" txt_i="24191" txt_f="24192">0</offsets></td><td><offsets xml_i="36349" xml_f="36356" txt_i="24193" txt_f="24200">1 (1.7)</offsets></td><td><offsets xml_i="36365" xml_f="36366" txt_i="24201" txt_f="24202">0</offsets></td><td><offsets xml_i="36375" xml_f="36382" txt_i="24203" txt_f="24210">4 (6.5)</offsets></td></tr><tr><td><offsets xml_i="36400" xml_f="36420" txt_i="24211" txt_f="24231">  Oropharyngeal pain</offsets></td><td><offsets xml_i="36429" xml_f="36430" txt_i="24232" txt_f="24233">0</offsets></td><td><offsets xml_i="36439" xml_f="36446" txt_i="24234" txt_f="24241">1 (1.7)</offsets></td><td><offsets xml_i="36455" xml_f="36456" txt_i="24242" txt_f="24243">0</offsets></td><td><offsets xml_i="36465" xml_f="36472" txt_i="24244" txt_f="24251">1 (1.7)</offsets></td><td><offsets xml_i="36481" xml_f="36482" txt_i="24252" txt_f="24253">0</offsets></td><td><offsets xml_i="36491" xml_f="36498" txt_i="24254" txt_f="24261">3 (4.9)</offsets></td><td><offsets xml_i="36507" xml_f="36514" txt_i="24262" txt_f="24269">4 (6.5)</offsets></td></tr><tr><td><offsets xml_i="36532" xml_f="36539" txt_i="24270" txt_f="24277">  Cough</offsets></td><td><offsets xml_i="36548" xml_f="36555" txt_i="24278" txt_f="24285">2 (3.4)</offsets></td><td><offsets xml_i="36564" xml_f="36565" txt_i="24286" txt_f="24287">0</offsets></td><td><offsets xml_i="36574" xml_f="36575" txt_i="24288" txt_f="24289">0</offsets></td><td><offsets xml_i="36584" xml_f="36591" txt_i="24290" txt_f="24297">1 (1.7)</offsets></td><td><offsets xml_i="36600" xml_f="36601" txt_i="24298" txt_f="24299">0</offsets></td><td><offsets xml_i="36610" xml_f="36611" txt_i="24300" txt_f="24301">0</offsets></td><td><offsets xml_i="36620" xml_f="36627" txt_i="24302" txt_f="24309">3 (4.8)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="36673" xml_f="36712" txt_i="24310" txt_f="24349">TEAE, treatment-emergent adverse event.</offsets></p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label><offsets xml_i="36776" xml_f="36783" txt_i="24350" txt_f="24357">Table 5</offsets></label><caption><p><offsets xml_i="36803" xml_f="36804" txt_i="24357" txt_f="24358">
</offsets><bold><offsets xml_i="36810" xml_f="36906" txt_i="24358" txt_f="24454">Change in clinical safety parameters from pre-dose values following treatment: safety population</offsets></bold><offsets xml_i="36913" xml_f="36914" txt_i="24454" txt_f="24455">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><offsets xml_i="36989" xml_f="37003" txt_i="24456" txt_f="24470">Placebo N = 59</offsets></th><th><offsets xml_i="37012" xml_f="37036" txt_i="24470" txt_f="24494">Salbutamol 400 μg N = 58</offsets></th><th><offsets xml_i="37045" xml_f="37071" txt_i="24494" txt_f="24520">Abediterol 0.313 μg N = 60</offsets></th><th><offsets xml_i="37080" xml_f="37106" txt_i="24520" txt_f="24546">Abediterol 0.625 μg N = 60</offsets></th><th><offsets xml_i="37115" xml_f="37140" txt_i="24546" txt_f="24571">Abediterol 1.25 μg N = 60</offsets></th><th><offsets xml_i="37149" xml_f="37173" txt_i="24571" txt_f="24595">Abediterol 2.5 μg N = 61</offsets></th></tr></thead><tbody><tr><td colspan="7"><offsets xml_i="37218" xml_f="37240" txt_i="24595" txt_f="24617">Serum glucose (mmol/L)</offsets></td></tr><tr><td><offsets xml_i="37258" xml_f="37277" txt_i="24618" txt_f="24637">  4 hours post-dose</offsets></td><td><offsets xml_i="37286" xml_f="37298" txt_i="24638" txt_f="24650">-0.37 (0.56)</offsets></td><td><offsets xml_i="37307" xml_f="37319" txt_i="24651" txt_f="24663">-0.24 (0.55)</offsets></td><td><offsets xml_i="37328" xml_f="37340" txt_i="24664" txt_f="24676">-0.19 (0.71)</offsets></td><td><offsets xml_i="37349" xml_f="37361" txt_i="24677" txt_f="24689">-0.27 (0.70)</offsets></td><td><offsets xml_i="37370" xml_f="37382" txt_i="24690" txt_f="24702">-0.16 (0.94)</offsets></td><td><offsets xml_i="37391" xml_f="37403" txt_i="24703" txt_f="24715">-0.23 (0.74)</offsets></td></tr><tr><td><offsets xml_i="37421" xml_f="37441" txt_i="24716" txt_f="24736">  24 hours post-dose</offsets></td><td><offsets xml_i="37450" xml_f="37461" txt_i="24737" txt_f="24748">0.01 (0.38)</offsets></td><td><offsets xml_i="37470" xml_f="37481" txt_i="24749" txt_f="24760">0.00 (0.33)</offsets></td><td><offsets xml_i="37490" xml_f="37501" txt_i="24761" txt_f="24772">0.13 (0.51)</offsets></td><td><offsets xml_i="37510" xml_f="37521" txt_i="24773" txt_f="24784">0.06 (0.62)</offsets></td><td><offsets xml_i="37530" xml_f="37541" txt_i="24785" txt_f="24796">0.11 (0.45)</offsets></td><td><offsets xml_i="37550" xml_f="37561" txt_i="24797" txt_f="24808">0.15 (0.59)</offsets></td></tr><tr><td colspan="7"><offsets xml_i="37591" xml_f="37615" txt_i="24809" txt_f="24833">Serum potassium (mmol/L)</offsets></td></tr><tr><td><offsets xml_i="37633" xml_f="37652" txt_i="24834" txt_f="24853">  4 hours post-dose</offsets></td><td><offsets xml_i="37661" xml_f="37673" txt_i="24854" txt_f="24866">-0.01 (0.36)</offsets></td><td><offsets xml_i="37682" xml_f="37694" txt_i="24867" txt_f="24879">-0.09 (0.38)</offsets></td><td><offsets xml_i="37703" xml_f="37715" txt_i="24880" txt_f="24892">-0.01 (0.35)</offsets></td><td><offsets xml_i="37724" xml_f="37735" txt_i="24893" txt_f="24904">0.10 (0.37)</offsets></td><td><offsets xml_i="37744" xml_f="37755" txt_i="24905" txt_f="24916">0.02 (0.36)</offsets></td><td><offsets xml_i="37764" xml_f="37776" txt_i="24917" txt_f="24929">-0.04 (0.35)</offsets></td></tr><tr><td><offsets xml_i="37794" xml_f="37814" txt_i="24930" txt_f="24950">  24 hours post-dose</offsets></td><td><offsets xml_i="37823" xml_f="37835" txt_i="24951" txt_f="24963">-0.02 (0.37)</offsets></td><td><offsets xml_i="37844" xml_f="37855" txt_i="24964" txt_f="24975">0.04 (0.34)</offsets></td><td><offsets xml_i="37864" xml_f="37875" txt_i="24976" txt_f="24987">0.05 (0.33)</offsets></td><td><offsets xml_i="37884" xml_f="37895" txt_i="24988" txt_f="24999">0.15 (0.32)</offsets></td><td><offsets xml_i="37904" xml_f="37915" txt_i="25000" txt_f="25011">0.04 (0.28)</offsets></td><td><offsets xml_i="37924" xml_f="37935" txt_i="25012" txt_f="25023">0.05 (0.38)</offsets></td></tr><tr><td colspan="7"><offsets xml_i="37965" xml_f="37981" txt_i="25024" txt_f="25040">Heart rate (bpm)</offsets></td></tr><tr><td><offsets xml_i="37999" xml_f="38017" txt_i="25041" txt_f="25059">  0.75 h post-dose</offsets></td><td><offsets xml_i="38026" xml_f="38036" txt_i="25060" txt_f="25070">-0.6 (9.1)</offsets></td><td><offsets xml_i="38045" xml_f="38055" txt_i="25071" txt_f="25081">2.0 (10.1)</offsets></td><td><offsets xml_i="38064" xml_f="38074" txt_i="25082" txt_f="25092">-0.7 (6.1)</offsets></td><td><offsets xml_i="38083" xml_f="38093" txt_i="25093" txt_f="25103">-0.8 (7.5)</offsets></td><td><offsets xml_i="38102" xml_f="38112" txt_i="25104" txt_f="25114">-1.5 (9.0)</offsets></td><td><offsets xml_i="38121" xml_f="38131" txt_i="25115" txt_f="25125">-0.8 (6.2)</offsets></td></tr><tr><td><offsets xml_i="38149" xml_f="38164" txt_i="25126" txt_f="25141">  2 h post-dose</offsets></td><td><offsets xml_i="38173" xml_f="38183" txt_i="25142" txt_f="25152">-3.4 (8.7)</offsets></td><td><offsets xml_i="38192" xml_f="38202" txt_i="25153" txt_f="25163">-1.0 (8.0)</offsets></td><td><offsets xml_i="38211" xml_f="38221" txt_i="25164" txt_f="25174">-2.0 (6.6)</offsets></td><td><offsets xml_i="38230" xml_f="38240" txt_i="25175" txt_f="25185">-3.4 (8.1)</offsets></td><td><offsets xml_i="38249" xml_f="38259" txt_i="25186" txt_f="25196">-4.3 (8.4)</offsets></td><td><offsets xml_i="38268" xml_f="38278" txt_i="25197" txt_f="25207">-3.2 (6.7)</offsets></td></tr><tr><td><offsets xml_i="38296" xml_f="38311" txt_i="25208" txt_f="25223">  6 h post-dose</offsets></td><td><offsets xml_i="38320" xml_f="38330" txt_i="25224" txt_f="25234">5.1 (10.2)</offsets></td><td><offsets xml_i="38339" xml_f="38348" txt_i="25235" txt_f="25244">7.2 (7.7)</offsets></td><td><offsets xml_i="38357" xml_f="38366" txt_i="25245" txt_f="25254">6.2 (7.1)</offsets></td><td><offsets xml_i="38375" xml_f="38384" txt_i="25255" txt_f="25264">6.2 (8.0)</offsets></td><td><offsets xml_i="38393" xml_f="38402" txt_i="25265" txt_f="25274">6.4 (9.8)</offsets></td><td><offsets xml_i="38411" xml_f="38420" txt_i="25275" txt_f="25284">5.3 (7.2)</offsets></td></tr><tr><td><offsets xml_i="38438" xml_f="38454" txt_i="25285" txt_f="25301">  24 h post-dose</offsets></td><td><offsets xml_i="38463" xml_f="38473" txt_i="25302" txt_f="25312">-2.1 (9.8)</offsets></td><td><offsets xml_i="38482" xml_f="38492" txt_i="25313" txt_f="25323">-1.9 (8.0)</offsets></td><td><offsets xml_i="38501" xml_f="38511" txt_i="25324" txt_f="25334">-1.6 (6.7)</offsets></td><td><offsets xml_i="38520" xml_f="38530" txt_i="25335" txt_f="25345">-0.8 (8.4)</offsets></td><td><offsets xml_i="38539" xml_f="38549" txt_i="25346" txt_f="25356">-0.9 (8.7)</offsets></td><td><offsets xml_i="38558" xml_f="38568" txt_i="25357" txt_f="25367">-0.6 (7.6)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="38614" xml_f="38649" txt_i="25368" txt_f="25403">Data are mean (standard deviation).</offsets></p><p><offsets xml_i="38656" xml_f="38678" txt_i="25404" txt_f="25426">bpm, beats per minute.</offsets></p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16" sec-type="discussion"><title><offsets xml_i="38774" xml_f="38784" txt_i="25430" txt_f="25440">Discussion</offsets></title><p><offsets xml_i="38795" xml_f="39125" txt_i="25441" txt_f="25771">In this study, abediterol 0.313, 0.625, 1.25, and 2.5 μg provided clinically and statistically significant improvements in peak bronchodilation versus placebo in patients with persistent, stable asthma. Abediterol doses ≥0.625 μg also caused bronchodilation compatible with once a day administration, as improvements in trough FEV</offsets><sub><offsets xml_i="39130" xml_f="39131" txt_i="25771" txt_f="25772">1</offsets></sub><offsets xml_i="39137" xml_f="39297" txt_i="25772" txt_f="25929"> &gt;250 mL compared with placebo were observed. The peak bronchodilatory effect of abediterol was similar to that of salbutamol 400 μg for all doses ≥0.625 μg.</offsets></p><p><offsets xml_i="39304" xml_f="39331" txt_i="25930" txt_f="25957">A mean increase in peak FEV</offsets><sub><offsets xml_i="39336" xml_f="39337" txt_i="25957" txt_f="25958">1</offsets></sub><offsets xml_i="39343" xml_f="39400" txt_i="25958" txt_f="26012"> &gt;200 mL is considered clinically relevant in asthma [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="39432" xml_f="39433" txt_i="26012" txt_f="26013">1</offsets></xref><offsets xml_i="39440" xml_f="39703" txt_i="26013" txt_f="26276">]. This magnitude of change was exceeded for all doses of abediterol, including the lowest dose, 0.313 μg. The primary objective of this study was to define abediterol doses that caused peak bronchodilation similar to salbutamol, the most widely prescribed SABA [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="39736" xml_f="39738" txt_i="26276" txt_f="26278">21</offsets></xref><offsets xml_i="39745" xml_f="39763" txt_i="26278" txt_f="26296">]. High doses of β</offsets><sub><offsets xml_i="39768" xml_f="39769" txt_i="26296" txt_f="26297">2</offsets></sub><offsets xml_i="39775" xml_f="39908" txt_i="26297" txt_f="26430">-agonists may increase the degree of bronchodilation but also can cause excessive systemic side effects through systemic absorption [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="39941" xml_f="39943" txt_i="26430" txt_f="26432">22</offsets></xref><offsets xml_i="39950" xml_f="40158" txt_i="26432" txt_f="26640">]. However, the current study demonstrates that the doses of abediterol from 0.625 to 2.5 μg induce acute bronchodilation similar to salbutamol, and therefore treatment with higher doses may not be warranted.</offsets></p><p><offsets xml_i="40165" xml_f="40425" txt_i="26641" txt_f="26901">Significant bronchodilation compared with placebo was achieved with a range of abediterol doses from 0.313 to 2.5 μg, consistent with the high potency of abediterol demonstrated in preclinical studies that suggested a potential for significant bronchodilation </offsets><italic><offsets xml_i="40433" xml_f="40440" txt_i="26901" txt_f="26908">in vivo</offsets></italic><offsets xml_i="40449" xml_f="40450" txt_i="26908" txt_f="26909">[</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="40482" xml_f="40483" txt_i="26909" txt_f="26910">7</offsets></xref><offsets xml_i="40490" xml_f="40621" txt_i="26910" txt_f="27041">]. Abediterol has higher potency than formoterol, salmeterol, indacaterol, olodaterol, and vilanterol in anesthetized guinea pigs [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="40653" xml_f="40654" txt_i="27041" txt_f="27042">7</offsets></xref><offsets xml_i="40661" xml_f="40663" txt_i="27042" txt_f="27044">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="40696" xml_f="40698" txt_i="27044" txt_f="27046">10</offsets></xref><offsets xml_i="40705" xml_f="40830" txt_i="27046" txt_f="27171">] as well as higher potency than salmeterol and indacaterol with comparable potency to formoterol in isolated human bronchi [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="40862" xml_f="40863" txt_i="27171" txt_f="27172">7</offsets></xref><offsets xml_i="40870" xml_f="40983" txt_i="27172" txt_f="27285">]. Based on the results of this preliminary dose-ranging study and the guidelines published by Chowdhury et al. [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="41016" xml_f="41018" txt_i="27285" txt_f="27287">16</offsets></xref><offsets xml_i="41025" xml_f="41129" txt_i="27287" txt_f="27391">], the clinically effective dose in asthma is considered most likely to be in the range of 0.625–2.5 μg.</offsets></p><p><offsets xml_i="41136" xml_f="41545" txt_i="27392" txt_f="27801">Significant bronchodilation compared with placebo was observed for salbutamol and all doses of abediterol at the first-assessed time point (15 min) post-dose; this indicates a rapid onset of action for both salbutamol and abediterol. Salmeterol and formoterol, both twice-daily LABAs, are widely used as maintenance therapy in COPD and asthma due to their longer durations of action compared with salbutamol [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="41577" xml_f="41578" txt_i="27801" txt_f="27802">6</offsets></xref><offsets xml_i="41585" xml_f="41587" txt_i="27802" txt_f="27804">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="41620" xml_f="41622" txt_i="27804" txt_f="27806">18</offsets></xref><offsets xml_i="41629" xml_f="41849" txt_i="27806" txt_f="28026">]. In clinical studies in patients with asthma, the onset of action of formoterol 24 μg is consistently faster than that of salmeterol 50 μg, with a median onset of action of 3.6 min compared with 31.0 min in one study [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="41882" xml_f="41884" txt_i="28026" txt_f="28028">23</offsets></xref><offsets xml_i="41891" xml_f="41893" txt_i="28028" txt_f="28030">, </offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="41926" xml_f="41928" txt_i="28030" txt_f="28032">24</offsets></xref><offsets xml_i="41935" xml_f="41938" txt_i="28032" txt_f="28035">]. </offsets><italic><offsets xml_i="41946" xml_f="41954" txt_i="28035" txt_f="28043">In vitro</offsets></italic><offsets xml_i="41963" xml_f="42143" txt_i="28043" txt_f="28223"> experiments in isolated human bronchi suggest that the onset of action of abediterol is faster than salmeterol and is not significantly different from formoterol and indacaterol [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="42175" xml_f="42176" txt_i="28223" txt_f="28224">7</offsets></xref><offsets xml_i="42183" xml_f="42185" txt_i="28224" txt_f="28226">].</offsets></p><p><offsets xml_i="42192" xml_f="42283" txt_i="28227" txt_f="28318">The prolonged duration of action of abediterol, with significant improvements in trough FEV</offsets><sub><offsets xml_i="42288" xml_f="42289" txt_i="28318" txt_f="28319">1</offsets></sub><offsets xml_i="42295" xml_f="42311" txt_i="28319" txt_f="28335">, normalized FEV</offsets><sub><offsets xml_i="42316" xml_f="42317" txt_i="28335" txt_f="28336">1</offsets></sub><offsets xml_i="42323" xml_f="42327" txt_i="28336" txt_f="28340"> AUC</offsets><sub><offsets xml_i="42332" xml_f="42336" txt_i="28340" txt_f="28344">0–24</offsets></sub><offsets xml_i="42342" xml_f="42558" txt_i="28344" txt_f="28560">, and trough FVC relative to placebo, and significant bronchodilation maintained up to 36 h post-dose is consistent with the results of previous clinical studies in healthy subjects and patients with COPD or asthma [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="42591" xml_f="42593" txt_i="28560" txt_f="28562">11</offsets></xref><offsets xml_i="42600" xml_f="42602" txt_i="28562" txt_f="28564">, </offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="42635" xml_f="42637" txt_i="28564" txt_f="28566">13</offsets></xref><offsets xml_i="42644" xml_f="42646" txt_i="28566" txt_f="28568">, </offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="42679" xml_f="42681" txt_i="28568" txt_f="28570">25</offsets></xref><offsets xml_i="42688" xml_f="42842" txt_i="28570" txt_f="28721">]. For example, a recent Phase II clinical study in patients with COPD demonstrated that abediterol 2.5, 5, and 10 μg achieved &gt;200 mL increases in FEV</offsets><sub><offsets xml_i="42847" xml_f="42848" txt_i="28721" txt_f="28722">1</offsets></sub><offsets xml_i="42854" xml_f="42986" txt_i="28722" txt_f="28854"> at 24 h, and that this bronchodilatory effect was greater than that of indacaterol 150 μg, and the duration of action was similar [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="43019" xml_f="43021" txt_i="28854" txt_f="28856">25</offsets></xref><offsets xml_i="43028" xml_f="43128" txt_i="28856" txt_f="28956">]. Taken together, these results are compatible with a once-daily dosing regimen in asthma and COPD.</offsets></p><p><offsets xml_i="43135" xml_f="43265" txt_i="28957" txt_f="29087">The convenience of once-daily dosing is likely to improve compliance in patients with asthma, leading to better patient outcomes [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="43298" xml_f="43300" txt_i="29087" txt_f="29089">26</offsets></xref><offsets xml_i="43307" xml_f="43309" txt_i="29089" txt_f="29091">, </offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="43342" xml_f="43344" txt_i="29091" txt_f="29093">27</offsets></xref><offsets xml_i="43351" xml_f="43541" txt_i="29093" txt_f="29283">], as shown in various studies, including that of Wells et al. whereby once-daily ICS led to improved compliance in patients with asthma compared with ICS administered multiple times daily [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="43574" xml_f="43576" txt_i="29283" txt_f="29285">28</offsets></xref><offsets xml_i="43583" xml_f="43992" txt_i="29285" txt_f="29694">]. LABA monotherapy treatment is contra-indicated in asthma; co-administration with an ICS is mandated, preferably as a fixed-dose combination to reduce the risk of monotherapy administration. Development of once-daily LABAs for use in fixed-dose combinations with once-daily ICS is important for simplifying treatment regimens and, therefore, helping improve patient compliance and general asthma management.</offsets></p><p><offsets xml_i="43999" xml_f="44150" txt_i="29695" txt_f="29846">The safety and tolerability profile of abediterol in this study is comparable to that reported in other studies in the abediterol development program [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="44183" xml_f="44185" txt_i="29846" txt_f="29848">11</offsets></xref><offsets xml_i="44192" xml_f="44193" txt_i="29848" txt_f="29849">–</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="44226" xml_f="44228" txt_i="29849" txt_f="29851">13</offsets></xref><offsets xml_i="44235" xml_f="44237" txt_i="29851" txt_f="29853">, </offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="44270" xml_f="44272" txt_i="29853" txt_f="29855">25</offsets></xref><offsets xml_i="44279" xml_f="44416" txt_i="29855" txt_f="29992">]. Single doses of abediterol 0.313–2.5 μg were safe and well tolerated, and the TEAEs were consistent with the known safety profile of β</offsets><sub><offsets xml_i="44421" xml_f="44422" txt_i="29992" txt_f="29993">2</offsets></sub><offsets xml_i="44428" xml_f="44438" txt_i="29993" txt_f="30003">-agonists.</offsets></p></sec><sec id="Sec17" sec-type="conclusions"><title><offsets xml_i="44494" xml_f="44504" txt_i="30005" txt_f="30015">Conclusion</offsets></title><p><offsets xml_i="44515" xml_f="45003" txt_i="30016" txt_f="30504">Abediterol 0.625–2.5 μg demonstrated a peak bronchodilatory response similar to that of a high dose of salbutamol (400 μg) at very low doses, and showed a clear dose–response relationship. Abediterol is a promising new, highly potent, LABA with a sustained duration of action and a favorable safety and tolerability profile. These results suggest that further studies are warranted to further evaluate the efficacy and safety of abediterol in combination with ICS in both asthma and COPD.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="45059" xml_f="45092" txt_i="30506" txt_f="30539">Electronic supplementary material</offsets></title><sec id="Sec18"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12890_2014_647_MOESM1_ESM.docx"><caption><p><offsets xml_i="45241" xml_f="45260" txt_i="30540" txt_f="30559">Additional file 1:
</offsets><bold><offsets xml_i="45266" xml_f="45302" txt_i="30559" txt_f="30595">Independent Ethics Committees (IEC).</offsets></bold><offsets xml_i="45309" xml_f="45322" txt_i="30595" txt_f="30608">
(DOCX 17 KB)</offsets></p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>ATS</term><def><p>American Thoracic Society</p></def></def-item><def-item><term>COPD</term><def><p>Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>ERS</term><def><p>European Respiratory Society</p></def></def-item><def-item><term>FEV<sub>1</sub> AUC</term><def><p>Area under the FEV<sub>1</sub> curve</p></def></def-item><def-item><term>FEV<sub>1</sub></term><def><p>Forced expiratory volume in 1 s</p></def></def-item><def-item><term>FVC</term><def><p>Forced vital capacity</p></def></def-item><def-item><term>GINA</term><def><p>Global Initiative for Asthma</p></def></def-item><def-item><term>ICS</term><def><p>Inhaled corticosteroid</p></def></def-item><def-item><term>IMP</term><def><p>Investigational medicinal product</p></def></def-item><def-item><term>LABA</term><def><p>Long-acting β<sub>2</sub>-adrenergic agonist</p></def></def-item><def-item><term>MDI</term><def><p>Metered dose inhaler</p></def></def-item><def-item><term>SABA</term><def><p>Short-acting β<sub>2</sub>-adrenergic agonist</p></def></def-item><def-item><term>TEAE</term><def><p>Treatment-emergent adverse event.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CIPLA, Forest, Genetech, GlaxoSmithKline, Merck, Novartis, Pfizer and Takeda. HP, AR, BS, EM, CA, SR and GdM are all employees of Almirall. BS, SR and GdM have a patent pending for abediterol (Novel dosage form and formulation of abediterol, WO2013178742 A1). HP, AR, BS and GdM hold Almirall shares or stocks.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>All authors contributed to the conception and design of the study, data analysis/interpretation and revision of the manuscript for important intellectual content and provided final approval of the manuscript. DS was the coordinating investigator of the study and drafted the article. There are no other contributors who fulfill the authorship criteria.</p></fn></fn-group><ack><p>The authors wish to thank the study investigators and PAREXEL International Ltd. Suzanne McAllister, PhD, from Complete Medical Communications provided medical writing assistance funded by Almirall S.A., Barcelona, Spain.</p><p>This study is registered with clinicaltrials.gov, trial registration number NCT01425801, and was funded by Almirall S.A., Barcelona, Spain.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other"><bold>Global Strategy for Asthma Management and Prevention</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.org">http://www.ginasthma.org</ext-link>]</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other"><bold>Ventolin Evohaler Summary of Product Characteristics</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/97/SPC">http://www.medicines.org.uk/emc/medicine/97/SPC</ext-link>]</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other"><bold>Serevent Accuhaler Summary of Product Characteristics</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/91">http://www.medicines.org.uk/emc/medicine/91</ext-link>]</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other"><bold>Formoterol Easyhaler Summary of Product Characteristics</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/19503/SPC">http://www.medicines.org.uk/emc/medicine/19503/SPC</ext-link>]</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other"><bold>Relvar Ellipta Summary of Product Characteristics</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/28496/SPC/">http://www.medicines.org.uk/emc/medicine/28496/SPC/</ext-link>]</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Novel long-acting bronchodilators for COPD and asthma</article-title><source>Br J Pharmacol</source><year>2008</year><volume>155</volume><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.284</pub-id><pub-id pub-id-type="pmid">18604231</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparici</surname><given-names>M</given-names></name><name><surname>Gómez-Angelats</surname><given-names>M</given-names></name><name><surname>Vilella</surname><given-names>D</given-names></name><name><surname>Otal</surname><given-names>R</given-names></name><name><surname>Carcasona</surname><given-names>C</given-names></name><name><surname>Viñals</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>I</given-names></name><name><surname>Gavaldá</surname><given-names>A</given-names></name><name><surname>De Alba</surname><given-names>J</given-names></name><name><surname>Gras</surname><given-names>J</given-names></name><name><surname>Cortijo</surname><given-names>J</given-names></name><name><surname>Morcillo</surname><given-names>E</given-names></name><name><surname>Puig</surname><given-names>C</given-names></name><name><surname>Ryder</surname><given-names>H</given-names></name><name><surname>Beleta</surname><given-names>J</given-names></name><name><surname>Miralpeix</surname><given-names>M</given-names></name></person-group><article-title>Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>342</volume><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1124/jpet.112.193284</pub-id><pub-id pub-id-type="pmid">22588259</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparici</surname><given-names>M</given-names></name><name><surname>Gómez-Angelats</surname><given-names>M</given-names></name><name><surname>Vilella</surname><given-names>D</given-names></name><name><surname>Cortijo</surname><given-names>J</given-names></name><name><surname>Morcillo</surname><given-names>EJ</given-names></name><name><surname>Carcasona</surname><given-names>C</given-names></name><name><surname>Gavaldà</surname><given-names>A</given-names></name><name><surname>Beleta</surname><given-names>J</given-names></name><name><surname>Puig</surname><given-names>C</given-names></name><name><surname>Ryder</surname><given-names>H</given-names></name><name><surname>Miralpeix</surname><given-names>M</given-names></name></person-group><article-title>The <italic>in vitro</italic> pharmacological profile of LAS100977 – a potent, selective and long-acting beta-2 receptor agonist [abstract A5675]</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>A5675</fpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miralpeix</surname><given-names>M</given-names></name><name><surname>Aparici</surname><given-names>M</given-names></name><name><surname>Carcasona</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>I</given-names></name><name><surname>Puig</surname><given-names>C</given-names></name><name><surname>Vilella</surname><given-names>D</given-names></name><name><surname>Gavalda</surname><given-names>A</given-names></name></person-group><source>Abediterol (LAS100977) is A Potent and Selective β<sub>2</sub>-Agonist with Sustained Duration of Action and Favourable Selectivity <italic>in Vitro</italic> [poster]</source><year>2014</year><publisher-loc>San Diego, CA, USA</publisher-loc><publisher-name>Presented at the American Thoracic Society Annual Congress</publisher-name></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>De Alba</surname><given-names>J</given-names></name><name><surname>Otal</surname><given-names>R</given-names></name><name><surname>Fernández-Blanco</surname><given-names>JA</given-names></name><name><surname>Aparici</surname><given-names>M</given-names></name><name><surname>Puig</surname><given-names>C</given-names></name><name><surname>Gavaldà</surname><given-names>A</given-names></name><name><surname>Miralpeix</surname><given-names>M</given-names></name></person-group><source>Abediterol (LAS100977) Demonstrates a Higher Potency and a Longer Duration of Action in Comparison with Other Long-Acting Β<sub>2</sub>-Adrenoceptor Agonists in a Guinea Pig Bronchoconstriction Model [poster]</source><year>2014</year><publisher-loc>San Diego, CA, USA</publisher-loc><publisher-name>Presented at the American Thoracic Society Annual Congress</publisher-name></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Fuhr</surname><given-names>R</given-names></name><name><surname>Massana</surname><given-names>È</given-names></name><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Seoane</surname><given-names>B</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name></person-group><article-title>Efficacy and safety of single inhaled doses of LAS100977, a novel long acting β<sub>2</sub>-agonist, in patients with persistent asthma [abstract A5414]</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>A5414</fpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miralpeix</surname><given-names>M</given-names></name><name><surname>Gomez-Angelats</surname><given-names>M</given-names></name><name><surname>Aparici</surname><given-names>M</given-names></name><name><surname>Vinals</surname><given-names>M</given-names></name><name><surname>Beleta</surname><given-names>J</given-names></name><name><surname>Gavalda</surname><given-names>A</given-names></name></person-group><article-title>LAS100977, a novel beta-2 receptor agonist, with a longer duration of action and more favourable safety margin than salmeterol in anesthetised dogs [abstract A5676]</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>A5676</fpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmer</surname><given-names>W</given-names></name><name><surname>Massana</surname><given-names>E</given-names></name><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Seoane</surname><given-names>B</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name></person-group><article-title>Single doses of LAS100977, a novel long acting β<sub>2</sub>-agonist, show high activity and long duration in healthy subjects [abstract A5663]</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>A5663</fpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Fuhr</surname><given-names>R</given-names></name><name><surname>Massana</surname><given-names>E</given-names></name><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Seoane</surname><given-names>B</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name></person-group><source>Efficacy and Safety of Single Inhaled Doses of LAS100977, A Novel Long Acting β<sub>2</sub>-Agonist, in Patients with Persistent Asthma [poster]</source><year>2010</year><publisher-loc>New Orleans, Louisiana, USA</publisher-loc><publisher-name>Presented at the American Thoracic Society International Conference</publisher-name></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Pujol</surname><given-names>H</given-names></name><name><surname>Seoane</surname><given-names>B</given-names></name><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Astbury</surname><given-names>C</given-names></name><name><surname>Massana</surname><given-names>E</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name></person-group><source>Efficacy and Safety of Abediterol (LAS100977) in Patients with COPD: Phase III, Randomized, Crossover Study [poster]</source><year>2013</year><publisher-loc>Barcelona, Spain</publisher-loc><publisher-name>Presented at the European Respiratory Society Annual Congress</publisher-name></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>B</given-names></name><name><surname>Seymour</surname><given-names>SM</given-names></name><name><surname>Michele</surname><given-names>TM</given-names></name><name><surname>Durmowicz</surname><given-names>AG</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Rosebraugh</surname><given-names>CJ</given-names></name></person-group><article-title>The risks and benefits of indacaterol–the FDA’s review</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>2247</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1109621</pub-id><pub-id pub-id-type="pmid">22168640</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whale</surname><given-names>CI</given-names></name><name><surname>Sovani</surname><given-names>MP</given-names></name><name><surname>Mortimer</surname><given-names>KJ</given-names></name><name><surname>Harrison</surname><given-names>TW</given-names></name><name><surname>Tattersfield</surname><given-names>AE</given-names></name></person-group><article-title>Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose–response study</article-title><source>Br J Clin Pharmacol</source><year>2008</year><volume>65</volume><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2007.03081.x</pub-id><pub-id pub-id-type="pmid">18394012</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Beier</surname><given-names>J</given-names></name></person-group><article-title>The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease</article-title><source>Adv Ther</source><year>2010</year><volume>27</volume><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1007/s12325-010-0017-6</pub-id><pub-id pub-id-type="pmid">20411368</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Burgos</surname><given-names>F</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><name><surname>van der Grinten</surname><given-names>CP</given-names></name><name><surname>Gustafsson</surname><given-names>P</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name><name><surname>MacIntyre</surname><given-names>N</given-names></name><name><surname>McKay</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Navajas</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>OF</given-names></name><name><surname>Wanger</surname><given-names>J</given-names></name></person-group><article-title>Interpretative strategies for lung function tests</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><fpage>948</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1183/09031936.05.00035205</pub-id><pub-id pub-id-type="pmid">16264058</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Tammeling</surname><given-names>GJ</given-names></name><name><surname>Cotes</surname><given-names>JE</given-names></name><name><surname>Pedersen</surname><given-names>OF</given-names></name><name><surname>Peslin</surname><given-names>R</given-names></name><name><surname>Yernault</surname><given-names>JC</given-names></name></person-group><article-title>Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</article-title><source>Eur Respir J Suppl</source><year>1993</year><volume>16</volume><fpage>5</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1183/09041950.005s1693</pub-id><pub-id pub-id-type="pmid">8499054</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crompton</surname><given-names>G</given-names></name></person-group><article-title>A brief history of inhaled asthma therapy over the last fifty years</article-title><source>Prim Care Respir J</source><year>2006</year><volume>15</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.pcrj.2006.09.002</pub-id><pub-id pub-id-type="pmid">17092772</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Page</surname><given-names>CP</given-names></name><name><surname>Calzetta</surname><given-names>L</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Pharmacology and therapeutics of bronchodilators</article-title><source>Pharmacol Rev</source><year>2012</year><volume>64</volume><fpage>450</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1124/pr.111.004580</pub-id><pub-id pub-id-type="pmid">22611179</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmqvist</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>G</given-names></name><name><surname>Lazer</surname><given-names>L</given-names></name><name><surname>Rosenborg</surname><given-names>J</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Lötvall</surname><given-names>J</given-names></name></person-group><article-title>Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency</article-title><source>Eur Respir J</source><year>1997</year><volume>10</volume><fpage>2484</fpage><lpage>2489</lpage><pub-id pub-id-type="doi">10.1183/09031936.97.10112489</pub-id><pub-id pub-id-type="pmid">9426083</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodzenta-Lukaszyk</surname><given-names>A</given-names></name><name><surname>Dymek</surname><given-names>A</given-names></name><name><surname>McAulay</surname><given-names>K</given-names></name><name><surname>Mansikka</surname><given-names>H</given-names></name></person-group><article-title>Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study</article-title><source>BMC Pulm Med</source><year>2011</year><volume>11</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/1471-2466-11-28</pub-id><pub-id pub-id-type="pmid">21605396</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Pujol</surname><given-names>H</given-names></name><name><surname>Seoane</surname><given-names>B</given-names></name><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Astbury</surname><given-names>C</given-names></name><name><surname>Massana</surname><given-names>E</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name><name><surname>de Miquel</surname><given-names>G</given-names></name></person-group><article-title>Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomized, crossover study [abstract 83]</article-title><source>Eur Respir J</source><year>2013</year><volume>42</volume><issue>Suppl 57</issue><fpage>183</fpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Cluley</surname><given-names>S</given-names></name><name><surname>Fabbri</surname><given-names>L</given-names></name></person-group><article-title>Improving patient compliance with asthma therapy</article-title><source>Respir Med</source><year>2000</year><volume>94</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/rmed.1999.0667</pub-id><pub-id pub-id-type="pmid">10714473</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makela</surname><given-names>MJ</given-names></name><name><surname>Backer</surname><given-names>V</given-names></name><name><surname>Hedegaard</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>K</given-names></name></person-group><article-title>Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD</article-title><source>Respir Med</source><year>2013</year><volume>107</volume><fpage>1481</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2013.04.005</pub-id><pub-id pub-id-type="pmid">23643487</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>KE</given-names></name><name><surname>Peterson</surname><given-names>EL</given-names></name><name><surname>Ahmedani</surname><given-names>BK</given-names></name><name><surname>Williams</surname><given-names>LK</given-names></name></person-group><article-title>Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence</article-title><source>Ann Allergy Asthma Immunol</source><year>2013</year><volume>111</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2013.06.008</pub-id><pub-id pub-id-type="pmid">23987199</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR29"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:
<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/14/176/prepub">http://www.biomedcentral.com/1471-2466/14/176/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>